

31

- 32 Biyun Zhang,
- 33 Professor
- ³⁴Central laboratory, Shanxi Cancer Hospital/Shanxi Hospital Affiliated to Cancer
- ³⁵Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi
- ³⁶Medical University, Taiyuan, 030013, China.
- 37 Tel: 86-18406593082
- ³⁸E-mail: z18406593082@163.com
- 39
- ⁴⁰Yongqiang Lv MD, PhD
- 41 Professor
- 42 Department of Quality Control, Shanxi Cancer Hospital/Shanxi Hospital Affiliated to
- 43 Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to
- ⁴⁴Shanxi Medical University, Taiyuan, China.
- ⁴⁵E-mail: lyq820529@163.com

Abstract

eTOC blurb

⁷⁵Kong et al. report extensive genetic correlations and genetic overlaps between blood 76 cell traits (BCTs) and cardiovascular diseases (CVDs), revealing key pleiotropic loci ⁷⁷and genes contributing to these associations, as well as multiple trait-specific 78 pathways mediating these phenotypic associations. Potential therapeutic targets to 79 inform future clinical interventions were also identified, laying the foundation for 80 understanding the genetic interactions between BCTs and CVDs.

81

⁸²**Introdution**

⁸³Cardiovascular diseases (CVDs), which encompass a range of conditions affecting the 84 heart and blood vessels, are the leading cause of death and disability worldwide^{1,2}. A 85 primary contributor to CVDs, atherosclerosis, is significantly influenced by various 86. blood cell traits $(BCTs)^{3,4}$. For example, erythrocytes, critical in maintaining 87 physiological hemodynamics, can exacerbate arterial wall pathologies and, through 88 interactions with immune cells, potentially accelerate atherosclerosis due to oxidative stress⁵. Similarly, the secretory functions of leukocytes, especially lymphocytes, are 90 pivotal as they release proinflammatory cytokines and proteases that may lead to 91. plaque rupture⁶. Platelets also play a key role in hemostasis and thrombosis and 92 enhancing the inflammatory environment, thus promoting the recruitment of 93 inflammatory cells to lesions and releasing inflammatory mediators⁷. Extensive 94 observational research has consistently demonstrated a robust association between 95 alterations in BCTs and increased risk of CVDs. Recent studies have identified 96 erythrocyte count (RBC), hematocrit (HCT), mean corpuscular volume (MCV), and 97 red cell distribution width (RDW-CV) as potential biomarkers for cardiovascular 98 risk.⁸. Additionally, conditions characteristic of CVDs can prompt the bone marrow to 99 release immature cells or increase other cell populations, depending on the severity. ¹⁰⁰Notably, the leukocyte is a cost-effective, widely used diagnostic tool in clinical 101 practice, with insights from the Framingham Heart Study highlighting its role as an 102 indicator of elevated CVD risks⁹. More precise predictions of CVD risk come from specific leukocyte subtypes, such as monocytes¹⁰, lymphocytes¹¹, and neutrophils¹², 104 rather than total leukocyte count (WBC) alone. Furthermore, studies have shown that

105 platelet metrics like platelet component distribution width (PDW), mean platelet 106 volume (MPV), and platelet count (PLT) are critical indicators of CVD risk¹³. These 107 insights underscore the importance of monitoring alterations in blood cell functions 108 for effective diagnosis, risk stratification, and predicting outcomes in CVDs.

109

¹¹⁰Epidemiological studies have consistently shown that BCTs are closely associated 111 with CVDs, with this relationship likely influenced by shared genetic factors $14,15$. ¹¹²Genome-wide association studies (GWAS) have identified numerous genetic variants 113 common to both BCTs and CVDs, such as *SH2B3* and *HFE*, which are associated 114 with RBC and coronary artery disease (CAD) , respectively¹⁶⁻¹⁸. This suggests that 115 pleiotropy, the influence of a single genetic variant on multiple traits, may be 116 fundamental to understanding the genetic basis of these complex traits. Pleiotropy 117 manifests in two primary forms: vertical and horizontal¹⁹. Vertical pleiotropy occurs 118 when single nucleotide polymorphisms (SNPs) influence one trait, which 119 subsequently affects another, permitting the use of Mendelian randomization (MR) to 120 estimate causal relationships between traits. For example, Hashfield *et al.* 121 demonstrated a positive causal relationship between PLT and eosinophil percentage of 122 leukocytes (EO_P) with an increased risk of ischemic stroke and its subtypes²⁰. ¹²³Similarly, genetic predispositions towards high RBC and low monocyte count 124 (MONO) correlate with increased venous thromboembolism (VTE) risk²¹. However, 125 existing MR studies have yet to explore these trait categories fully. On the other hand, ¹²⁶horizontal pleiotropy occurs when a genetic variant independently affects multiple 127 phenotypes or influences intermediate processes between these phenotypes. Recent 128 advances in statistical tools for genomics have underscored the importance of 129 horizontal pleiotropy in elucidating the shared genetic basis of complex traits. For 130 example, Yang *et al.* reported an extensive landscape of genetic correlations between 131 29 BCTs and 11 neurological and psychiatric diseases²². Despite these insights, ¹³²previous studies have yet to comprehensively explore the relationship between BCTs ¹³³and CVDs. The complex association patterns and underlying mechanisms of their 134 connection remain largely uncharted. Therefore, systematic analyses are necessary to

- ¹³⁵determine whether shared genetic architectures and molecular pathways exist between
- 136 BCTs and CVDs, potentially unveiling new insights into their biological mechanisms.
- 137

¹³⁸In this study, we comprehensively analyzed the latest and most extensive GWAS ¹³⁹summary data from individuals of European ancestry to uncover the shared genetic 140 architecture and mechanisms underlying 29 BCTs and six major CVDs (Table 1). Our 141 initial analyses focused on identifying the shared genetic structure between BCTs and ¹⁴²CVDs, utilizing methods to analyze genetic correlations and overlaps. Then, ¹⁴³employing MR analysis within a framework of vertical pleiotropy, we explored ¹⁴⁴evidence for causal relationships between BCTs and CVDs. This groundwork ¹⁴⁵facilitated a cross-trait analysis, pinpointing pleiotropic SNPs at the SNP level, and 146 allowed us to identify candidate pleiotropic genes through positional mapping and 147 expression quantitative trait loci (eQTL) mapping. Further investigations included an ¹⁴⁸enrichment analysis of biological pathways and the identification of pathogenic 149 plasma proteins, assessing their potential as therapeutic targets. This multifaceted ¹⁵⁰approach has illuminated complex genetic networks linking hematological markers to 151 cardiovascular health, offering insights that could pave the way for novel diagnostic 152 and therapeutic strategies.

153

¹⁵⁴**Result**

¹⁵⁵**Genome-wide genetic correlation between BCTs and CVDs**

156 We assessed the SNP-based heritability (h^2_{SNP}) of 29 BCTs and 6 major CVDs using ¹⁵⁷linkage disequilibrium (LD) score regression (LDSC) and performed genome-wide 158 genetic correlation (r_g) analysis of these 174 trait pairs. Univariate LDSC analysis showed that h^2_{SNP} estimates for BCTs were consistently higher than those for CVDs, ranging from 5.2% to 34.9%, with the highest estimate for MPV $(h^2_{SNP} = 34.88\%$, SE $= 0.036$). In contrast, h^2_{SNP} estimates for CVDs were significantly lower, all below 5%, 162 with the smallest estimate for Stroke $(h^2_{SNP} = 0.60\%$, SE = 0.0005) and the highest 163 estimate for CAD ($h^2_{SNP} = 3.25\%$, SE = 0.0019) (Supplementary Table 1). Subsequent ¹⁶⁴bivariate LDSC analysis found nominally significant associations for 36 (20.3%) of

165 174 trait pairs ($P < 0.05$). Of these, 26 trait pairs showed positive r_g , especially 166 between WBC and PAD, with a r_g of 0.115 (SE = 0.053). In contrast, the most 167 significant negative r_g was between mean corpuscular hemoglobin concentration 168 (MCHC) and VTE, with a r_g of -0.101 (SE = 0.028). Using a less stringent 5% false 169 discovery rate (FDR) threshold, we found that three blood cell count-related traits, 170 including platelet crit (PCT), PLT, and MCHC, were associated with a lower risk of ¹⁷¹VTE. Six different BCTs (neutrophil count (NEUT), WBC, high light scatter 172 reticulocyte count (HLR), high light scatter percentage of red cells (HLR_P), 173 reticulocyte count (RET), and reticulocyte fraction of red cells (RET_P)) were 174 significantly associated with an increased risk of CAD. In contrast, six different BCTs ¹⁷⁵(immature fraction of reticulocytes (IRF), mean corpuscular hemoglobin (MCH), ¹⁷⁶MCV, mean reticulocyte volume (MRV), mean spheric corpuscular volume (MSCV), 177 and red cell distribution width (RDW_CV) were significantly associated with an 178 increased risk of VTE. Notably, four trait pairs previously identified as having the 179 same direction of genetic correlations (including HLR-CAD, MRV-VTE, MCV-VTE, 180 and RDW_CV-VTE) confirmed significant correlations between them^{21,23-26} (Fig. 1 181 and Supplementary Table 2).

182

¹⁸³**Local genetic correlation between BCTs and CVDs**

¹⁸⁴LDSC is used to estimate additive genetic effects on traits across the genome, 185 however, when genetic signals show opposite correlations in different genomic 186 regions, the cumulative genome-wide r_g can asymptotically approach zero. To address 187 this issue, we used Local Analysis of [co] Variant Annotation (LAVA) to perform ¹⁸⁸more detailed analyses within shorter genomic regions, specifically focusing on local ¹⁸⁹genetic correlations (local-*rgs*) between 29 BCTs and 6 CVDs. Applying it to 80,126 190 regions, we identified 28,887 univariate genetic signals associated with BCTs in 2,219 191 unique regions and 2,716 signals associated with CVDs in 1,472 unique regions, all 192 with p-values less than 1×10^{-4} (Supplementary Table 3). Subsequent bivariate analysis 193 revealed significant local- $r_{\rm g}$ s (FDR < 0.05) for all trait pairs, covering 5,233 genetic 194 regions (including 898 unique regions)(Supplementary Fig.1 and Supplementary

195 Table 4). Interestingly, there is mixed local genetic effects on trait pairs where 196 genome-wide r_g is not significant. For example, between MSCV and CAD, 41.4% of 197 the partitions showed positive associations, 59.6% showed negative associations, 198 suggesting that genome-wide r_g may underestimate the polygenic overlap of these 199 trait pairs. Notably, LD block 1841 on chromosome 12 was associated with more than 200 half of the trait pairs, followed by LD block 1479 on chromosome 9 and LD block ²⁰¹1480 on chromosome 12, which showed correlations with 68 and 47 trait pairs, 202 respectively. Then, Hypothesis Prioritisation for multi-trait Colocalization ²⁰³(HyPrColoc) further identified the common causal variants among them and indicated 204 a high association frequency for pleiotropic SNPs in the $12q24.12$ region. Notably, ²⁰⁵rs3184504 (mapped to the *SH2B3* gene) showed strong evidence of colocalization 206 between 19 BCTs and 2 CVDs (CAD and VTE), with a posterior probability (PP) $>$ ²⁰⁷0.7. In addition, rs4378452 (mapped to the *CUX2* gene) was identified as a potential 208 common causal variable between 22 BCTs and CAD.

209

²¹⁰**Extensive genetic overlap between BCTs and CVDs**

211 Consider that r_g can not characterize detailed association patterns at individual loci, 212 and nonsignificant estimates do not necessarily indicate the absence of a common 213 genetic background. Therefore, we further applied genetic analysis combining 214 pleiotropy and annotation (GPA) approach to explore the overlapping genetic variants 215 of 29 BCTs and 6 CVDs, enhancing the understanding of the common genetic 216 landscape of BCTs and CVDs. GPA analysis revealed that all BCTs-CVDs trait pairs 217 exhibited varying degrees of genetic overlap at a 5% FDR threshold, regardless of 218 whether the genome-wide r_g was significant (Supplementary Fig.2 and Supplementary 219 Table 5). Notably, reticulocyte count (RET) and CAD showed a relatively high 220 proportion of shared SNPs (proportion of association ratio $(PAR) = 25.4\%$), consistent 221 with their significant genetic correlation ($r_g = 0.107$). Among the 138 BCTs-CVDs 222 pairs with non-significant genome-wide r_g , the overlap between CAD and MSCV was 223 particularly pronounced, with a shared genetic overlap of 24.1%. As for IRF-VTE, as 224 a significant genome-wide r_g trait pair, the proportion of pleiotropic SNPs is only

225 19.0%, which is lower than MSCV-CAD. In summary, we confirmed the presence of 226 shared genetic structure in all trait pairs using LAVA and GPA approaches. Although 227 some trait pairs did not show evidence of genome-wide r_g , possibly due to 228 confounding effects, our analyses highlight potential genetic links that contribute to 229 the complex relationship between BCTs and CVDs.

230

²³¹**Mendelian Randomization between BCTs and CVDs**

²³²To investigate vertical pleiotropy between 29 BCTs and 6 CVDs, we employed Latent ²³³Heritable Confounder Mendelian Randomization (LHC-MR) to evaluate causal 234 relationships. The forward analysis identified seven causal relationships that achieved ²³⁵Bonferroni-corrected significance, including positive associations for RDW-VTE, 236 basophil percentage of leukocytes (BASO_P)-AF, and BASO_P-CAD. For example, 237 an elevated RDW_CV was associated with an increased risk of VTE (OR $= 1.08$), 238 whereas a higher IRF was linked to a reduced risk of CAD (OR $= 0.91$), indicating 239 negative causal relationships. The reverse analysis uncovered twelve positive causal 240 relationships, such as AF, with an increased MCV (OR $= 1.52$). In contrast, four pairs 241 showed negative causal relationships, notably VTE associated with a decreased 242 RDW_CV (OR $= 0.71$). Remarkably, only the pair PCT-CAD exhibited a bidirectional 243 causal relationship. These findings suggest that although some trait pairs demonstrate 244 distinct causal connections, most associations between BCTs and CVDs are not driven ²⁴⁵by underlying causal factors(Fig. 2, Supplementary Fig. 3, Supplementary Table 6 and 246 Supplementary Table 7).

247

²⁴⁸**Shared Loci between BCTs and CVDs**

²⁴⁹Although the above three approaches have enhanced our understanding of the general 250 pleiotropy between BCTs and CVDs, they still need to elaborate on the association 251 patterns of individual loci and clarify their shared genetic architecture from the 252 perspective of vertical and horizontal pleiotropy. To fill this gap, we employed the ²⁵³Pleiotropic Analysis under the Composite Null Hypothesis (PLACO) to identify 254 horizontal pleiotropic SNPs mediating the association between BCTs and CVDs. A

255 total of 571,782 SNPs ($P < 5 \times 10^{-8}$) were identified as significant pleiotropic variants 256 across all BCT-CVD pairs (Fig. 3 and Supplementary Table 8). Notably, the PLT-CAD 257 pair exhibited the most pleiotropic associations with 176 pleiotropic SNPs, followed 258 closely by RBC-CAD (173 pleiotropic SNPs) and MSCV-CAD (168 pleiotropic ²⁵⁹SNPs), consistent with the significant genetic overlap between these trait pairs. 260 Subsequently, 571,782 pleiotropic SNPs were clustered into 13,697 genomic loci in ²⁶¹580 unique chromosomal regions using functional mapping and annotation (FUMA). ²⁶²Specifically, 11,810 loci were associated with BCTs, 3,904 with CVDs, and 2,622 263 were shared between BCTs and CVDs. Notably, 12 chromosomal regions were shared 264 by at least half of the trait pairs, including regions $9q34.2$, $12q24.12$, $12q24.31$, and 265 19p13.2. We also observed mixed directions of allelic associations, with 6,721 top ²⁶⁶SNPs (49.1%) consistently associated with specific traits, indicating that these 267 variants can either simultaneously reduce $(3,185$ SNPs) or increase $(3,536$ SNPs) the 268 number/percentage of BCTs and CVDs risks. In contrast, the remaining 50.9% of the 269 top SNPs showed opposite associations with specific traits, suggesting the presence of 270 different biological mechanisms.

271

272 For functional annotation, we utilized ANNOVAR and discovered that 8,201 (59.9%) 273 of the variants were intronic, $3,749$ (27.4%) were intergenic, and 523 (3.8%) were 274 exonic. Among these, the index SNP rs1613662 at the 19q13.42 locus ($P_{PLACO} = 9.26$) $\times 10^{-10}$ for basophil count BASO-VTE and PLT-VTE) was related to an adipose 276 visceral omentum eQTL ($P_{Adipose_Visceral_Omentum} = 1.49 \times 10^{-5}$), encoding the collagen 277 receptor GPVI/FcRγ, primarily involving *GP6* variants (Supplementary Table 10). 278 This receptor interaction with subendothelial collagen exposed after vessel wall injury 279 can promote platelet activation and aggregation, thus affecting the risk of VTE^{27} . ²⁸⁰Additionally, combined annotation-dependent depletion (CADD) scores revealed that 281 1,031 SNPs had scores greater than 12.37, with $rs116843064$ in the 19p13.2 region 282 having the highest CADD score of 33. A total of 484 top SNPs were found to

283 potentially affect transcription factor binding and correlate with gene target 284 expression. Among these, six SNPs, including rs4987082, rs12440045, rs6511703, ²⁸⁵rs1214761, rs9810512, and rs6882088, had the highest credibility for regulatory 286 functions (RegulomeDB score: 1a). We further performed colocalization analysis on ²⁸⁷13,697 potential pleiotropic loci, of which 1,709 (12.5%) showed strong 288 colocalization evidence (PPH4 > 0.7). Notably, the 12q24.31 locus affected 46 trait 289 pairs, with PP.H4 values ranging from 0.740 to 0.995, demonstrating significant 290 pleiotropy.

291

²⁹²**Candidate pleiotropic genes by position mapping**

²⁹³We further integrated these pleiotropic SNPs to the gene level using multi-marker ²⁹⁴analysis of genomic annotation (MAGMA) and identified 10,106 significant 295 pleiotropic genes (1,973 unique genes) $(P < 1.63 \times 10^{-8})$ (Fig. 3, Supplementary Table 296 12). Notably, 1,453 (73.6%) of these genes were widely shared between two or more 297 trait pairs. For example, *ATXN2*, *ACAD10*, *ALDH2*, *CUX2*, *BRAP*, *SH2B3*, and ²⁹⁸*MAPKAPK5* were identified as significant pleiotropic genes in 69, 67, 64, 61, 58, 58 299 and 56 trait pairs, respectively. These genes are located in the $12q24.11-12q24.13$ 300 region, known for its pleiotropic effects on PCT and various cardiometabolic traits, 301 including fasting glucose, blood pressure, and obesity-related traits (body mass index ³⁰²(BMI) and waist-to-hip ratio (WHR)). Depleting the cytoplasmic protein encoded by ³⁰³*ATXN2* has resulted in defective platelet aggregation and dysregulation of hemostatic 304 processes²⁸. Additionally, polymorphisms in *ATXN2* significantly affect the 305 kynurenine level in erythrocytes²⁹ and are critical loci for systolic (SBP) and diastolic 306 blood pressure (DBP), as well as mean arterial pressure $(MAP)^{30}$. Consequently, ³⁰⁷*ATXN2* plays a pivotal role in the onset of various CVD events by regulating blood 308 pressure. To ensure the robustness of our findings, SNPs were positionally remapped ³⁰⁹using the SNP2GENE function of FUMA, which verified 88.5% of the genes 310 identified by MAGMA (Supplementary Table 10). Further comparisons of the ³¹¹PLACO-based MAGMA results with single trait GWAS data for BCTs and CVDs

312 revealed 855 (8.5%) novel genes for BCTs, 4,938 (48.9%) novel genes for CVDs, and

313 229 genes that overlapped between BCTs and CVDs (Supplementary Table 12).

314

³¹⁵**Candidate tissue-specific pleiotropic genes by eQTL mapping**

316 To elucidate how the above SNPs affect gene expression in a tissue-specific manner, ³¹⁷we first used LDSC-specific expression (LDSC-SEG) to determine the tissue 318 association corresponding to each trait. We found that BCTs-related traits were mainly 319 significantly enriched in Adipose_Visceral_(Omentum), Cells_EBV-320 transformed_lymphocytes, Lung, Small_Intestine_Terminal_Ileum and Whole_Blood 321 tissues (FDR < 0.05) (Supplementary Fig. 4, Supplementary Table 15A). In CVDs, ³²²AF showed significant enrichment in heart-related tissues (Heart_Atrial_Appendage ³²³and Heart_Left_Ventricle), while CAD showed considerable enrichment in 324 artery-related tissues (Artery_Aorta, Artery_Coronary, and Artery_Tibial). Subsequent ³²⁵LDSC-SEG chromatin analysis showed that BCTs were mostly significantly enriched 326 in primary cells from peripheral blood (Supplementary Table 15B). In CVDs, AF was ³²⁷mainly enriched in the fetal heart, and CAD was significantly enriched in the aorta 328 and coronary artery, confirming the multi-tissue gene expression results.

329

³³⁰To overcome the limitation of the MAGMA approach (assigning SNPs to the nearest 331 gene without considering functional association), we employed eQTL Multi-marker ³³²Analysis of GenoMic Annotation (eMAGMA) to link tissue-specific cis-eQTL 333 information to genes to generate more biologically meaningful results (Supplementary ³³⁴Table 16). From an analysis of 10 selected tissues, we identified 2,328 unique 335 pleiotropic genes achieving Bonferroni-corrected significance, each highly enriched 336 in at least one specific tissue. Notably, $1,875$ of these genes (80.5%) were present in 337 two or more trait pairs. Among them, genes such as *ABO* ($n=125$), *TMEM116* ($n=99$), ³³⁸*ALDH2* (n=95), and *MAPKAPK5* (n=87) appeared in over half of the trait pairings, ³³⁹each demonstrating specific tissue enrichments. In particular, the *ABO* gene is 340 predominantly found in liver and visceral adipose tissues; *TMEM116* in the artery 341 tibial and visceral adipose tissues; *ALDH2* in both artery tibial and artery aorta tissues;

³⁴²and *MAPKAPK5* in adipose subcutaneous and visceral adipose tissues. Notably, the ³⁴³*ABO* gene affects the serum levels of von Willebrand factor (vWF) and soluble $B-₅ = 344$ E-selectin³¹, which are involved in thrombosis and endothelial dysfunction, 345 respectively, and are critical for the development of cerebrovascular injury and 346 atherosclerosis $31,32,33,34$. We further used the single-trait GWAS results to conduct 347 transcriptome-wide association study (TWAS) to identify tissue-specific pleiotropic ³⁴⁸genes for complex traits and found 5,609 novel genes for BCTs and 20 novel genes ³⁴⁹for CVDs (Supplementary Table 17). Notably, genes such as *ABO* and *ALDH2* were 350 identified in more than half of the trait pairs, and both eQTL-based strategies ³⁵¹highlighted that *ALDH2* in the 12q24.12 region was associated with a common ³⁵²molecular mechanism for BCTs and CVDs, which may mediate CVDs 353 pathophysiology by affecting the metabolism of reactive aldehydes under oxidative 354 stress. However, the exact role of *ALDH2* in the blood phenotype remains to be ³⁵⁵elucidated. In addition, we further validated 81.7% of the genes identified by 356 eMAGMA using eQTL mapping using FUMA (Supplementary Table 10).

357

In our study, MAGMA and eMAGMA analyses identified 5,063 pleiotropic genes, of which 936 (313 unique) exhibited strong evidence of colocalization and were included in subsequent analyses (Supplementary Table 8 and Supplementary Table 361 12). Notably, 194 of these genes demonstrated pleiotropic effects across two or more BCT-CVD trait pairs, including significant genes such as *ALDH2*, *PHETA1*, and *MAPKAPK5* (all located at 12q24.12), *CCDC92* (12q24.31), and *ZNF664* (12q24.31). Interestingly, the degree of pleiotropy varied significantly among some genes across 365 different categories of trait pairs. For instance, of the 18 trait pairs associated with *ACAD10*, 15 involved Leukocyte-CVD pairs, while the remaining 3 were Erythrocyte-CVD. Similarly, *CCDC92* appeared in 20 trait pairs, with 15 categorized 368 as Erythrocyte-CVD, accounting for 17.9% of the total Erythrocyte-CVD. Conversely, *CCDC92* featured less frequently in Leukocyte-CVD (4 pairs, representing 6.1% of 370 all such pairs) and Platelet-CVD (only 1 pair, or 4.2% of these pairings).

371

³⁷²Therefore, considering that the association of genes with CVDs may be influenced by ³⁷³BCT type, we categorized all BCTs-CVDs trait pairs into three groups based on BCT 374 types, including Leukocytes-CVDs, Platelets-CVDs, and Erythrocytes-CVDs, with 375 pleiotropic gene counts of 174, 117, and 164, respectively. Among the ³⁷⁶Leukocytes-CVDs trait pairs, *ACAD10,* one of the specific genes, is not associated ³⁷⁷with Leukocytes-AF. *ACAD10* is critical in mitochondrial fatty acid β-oxidation, 378 influencing leukocyte functions such as proliferation, cytokine production, and 379 adhesion molecule production. It is also an essential energy source for 380 cardiomyocytes, underscoring its significant role in CVD pathophysiology³⁵. Among 381 the Platelets-CVDs pairs, *TNFSF12* (*TWEAK*) was notably associated with PCT and ³⁸²AF. The interaction of *TNFSF12* with the fibroblast growth factor-inducible molecule ³⁸³14 (Fn14) activates signaling pathways essential for vascular and cardiac remodeling, 384 pivotal in acute and chronic CVDs³⁶. Furthermore, studies have linked serum *TWEAK* 385 levels to PLT, highlighting clinical relevance^{33,37}. For the Erythrocytes-CVDs pairs, ³⁸⁶*CCDC92* was the most frequently pleiotropic gene, which affects the occurrence of 387 cardiovascular events by regulating adipose tissue distribution and insulin sensitivity, 388 highlighting its broad impact on metabolic and cardiovascular health 38,39 .

389

³⁹⁰**Potential shared biological mechanism between BCTs and CVDs**

³⁹¹We performed MAGMA gene set analysis to explore specific biological pathways or 392 cellular functions implicated in the BCTs-CVDs pair's genetic etiology. A total of 393 1,599 pathways were significantly enriched after Bonferroni correction ($P < 3.00 \times$ 394 10^{-8}), including 169 Gene Ontology Biological Process (GO BP) terms, 30 KEGG 395 pathways, and 33 Reactome pathways (Supplementary Table 18). Since most genes ³⁹⁶have obvious trait specificity and participate in different biological pathways, we still 397 divide the pathways enriched by BCTs-CVDs into three categories to observe whether ³⁹⁸they have specific and reliable results. Of these, 992 were associated with the ³⁹⁹Leukocytes-CVDs pairs, and more than half of these involved pathways were related 400 to the regulation of immune system processes, immune responses, and cellular

401 activation, affecting all leukocyte phenotypes except basophil-related parameters. In 402 contrast, the Platelets-CVDs pairs were enriched for only 77 pathways, mainly related 403 to hemostasis and platelet activation, signaling, and aggregation. VTE showed strong 404 correlations with all four platelet parameters in these specific pathways. For the ⁴⁰⁵Erythrocytes-CVDs pairs, 530 pathways were enriched, mainly involving vascular 406 and circulatory system development, with AF and CAD being more highly associated 407 with these terms than other CVDs.

408

⁴⁰⁹Further enrichment analysis of overlapping genes in MAGMA and eMAGMA 410 analyses using Metascape confirmed that the Leukocytes-CVDs related gene set was ⁴¹¹mainly involved in the inflammatory response, the Platelets-CVDs related gene set ⁴¹²focused on platelet activation and aggregation, and the Erythrocytes-CVDs related ⁴¹³gene set was mainly engaged in the regulation of hematopoietic progenitor 414 differentiation, which is highly consistent with the results of the MAGMA gene set ⁴¹⁵analysis(Supplementary Table 19). These findings revealed the common molecular 416 genetic mechanisms behind the extensive multi-gene overlap between the three types 417 of BCTs and CVDs, highlighting important pathways that may become therapeutic 418 targets for treating these diseases.

419

⁴²⁰**Identification of pathogenic proteins and drugs in cross-sectional traits**

⁴²¹To investigate the associations between plasma protein expression and disease risk, 422 we employed summary-data-based Mendelian Randomization (SMR). We sourced ⁴²³blood cis-pQTL data from the UK Biobank Pharmaceutical Proteomics Project ⁴²⁴(UKB-PPP) and the deCODE Health study. After excluding entries that failed the ⁴²⁵heterogeneity in dependent instruments (HEIDI) test, underwent multiple SNP-SMR 426 sensitivity analyses, and surpassed the Bonferroni correction threshold, we identified ⁴²⁷1,589 causal proteins, of which 1,534 were associated with BCTs and 55 with CVDs. ⁴²⁸Among these, 49, 62, and 101 overlapping proteins were associated with leukocytes, 429 platelets, and erythrocytes, respectively, from deCODE Health and UKB-PPP studies, 430 with an additional eight proteins linked to CVDs. Remarkably, our analysis uncovered

431 only three pleiotropic proteins across seven distinct trait pairs, specifically SERPINE2 ⁴³²and TNFSF12 in Platelets-CVDs pairs and GP6 in both Platelets-CVDs and ⁴³³Erythrocytes-CVDs pairs. Subsequent colocalization analysis confirmed that the GP6 434 gene polymorphic variant rs892090 demonstrated strong colocalization in all pertinent 435 trait pairs except MPV-VTE (Supplementary Table 20).

436

⁴³⁷**Discussion**

⁴³⁸We discovered significant genetic overlaps between BCTs and CVDs through 439 comprehensive pleiotropic analyses of large-scale GWAS summary statistics. ⁴⁴⁰However, evidence for a direct causal relationship remains limited. Our studies 441 identified 571,782 pleiotropic variants and 313 unique pleiotropic genes, which show ⁴⁴²varied CVD risks across different BCT subgroups, including leukocytes, platelets, and ⁴⁴³erythrocytes. We further explored the distinct characteristics of these blood cell ⁴⁴⁴phenotypes, revealing that specific pathways play key roles in their pathophysiology. ⁴⁴⁵For platelet-CVD subgroups, platelet activation is central; for erythrocyte-CVD ⁴⁴⁶subgroups, the regulation of hematopoietic progenitor differentiation is crucial; and 447 for leukocyte-CVD subgroups, the inflammatory response is pivotal. Additionally, our ⁴⁴⁸research has identified GP6, TNFSF12, and SERPINE2 as potential therapeutic 449 targets for these conditions. These findings underscore the value of BCT parameters 450 as biomarkers for assessing CVD risk and provide valuable insights into the genetic 451 underpinnings of these associations.

452

⁴⁵³We identified a substantial genetic overlap between BCTs and CVDs using diverse ⁴⁵⁴analytical methodologies, including LDSC, GPA, and LAVA. Our analysis indicated ⁴⁵⁵significant genome-wide genetic correlations for 8.6% of trait pairs, corroborating 456 previous phenotypic associations and confirming a shared genetic foundation. 457 Although genome-wide r_g (averaging shared SNP effects across the genome) may 458 obscure specific genetic associations within genomic regions, we utilized LAVA to 459 pinpoint multiple specific genomic areas. We observed local- r_{ε} s for all trait pairs 460 within these regions, indicating confounding effects that are not evident in

461 genome-wide estimates. For instance, despite a genome-wide r_g near zero according 462 to LDSC, both BASO_P-AF and BASO-CAD demonstrated approximately equal ⁴⁶³numbers of positively and negatively correlated genetic regions. This nuance ⁴⁶⁴underscores significant genetic correlations that broader statistical frameworks might 465 overlook. Our GPA analysis further confirmed substantial polygenic overlap among 466 all trait pairs, highlighting the complex genetic interplay between BCTs and CVDs. In 467 conclusion, our study reveals an extensive shared genetic liability between BCTs and ⁴⁶⁸CVDs, suggesting that their relationships are more robust and intricate than 469 previously recognized.

470

471 The LHC-MR method explored the causal relationship at the level of vertical ⁴⁷²pleiotropy, which can reveal part of the common genetic mechanisms between BCTs 473 and CVDs. We identified 23 putative causal relationships, especially positive ones in ⁴⁷⁴RDW_CV-VTE, Stroke-eosinophil count (EO), and Stroke-PCT, consistent with 475 previous studies^{20,40}. The causal link for RDW_CV-VTE may be the reduced 476 deformability and increased aggregation of red blood cells, elevating viscosity and ⁴⁷⁷impeding blood flow, thereby increasing VTE risk. Conversely, our findings did not 478 confirm the previously reported associations between high neut and increased risks of 479 AF, HF, PAD, and Stroke, as suggested by Jiao *et* $al⁴¹$. This discrepancy could stem 480 from the significant sample overlap between BCTs and CVDs GWAS samples in the ⁴⁸¹UK Biobank, a typical challenge in two-sample Mendelian randomization analyses. 482 Our LHC-MR approach addressed and mitigated genetic confounding due to this ⁴⁸³sample overlap and clarified the exposure-outcome relationships. Additionally, we 484 report for the first time a positive association between HF and several BCTs, such as ⁴⁸⁵MPV, MSCV, PCT, and PLT, and a negative association with HCT. However, the 486 negative relationship between AF and PLT is consistent with previous studies. ⁴⁸⁷Specifically, a meta-analysis by Alexander *et al*. indicated a significant reduction in ⁴⁸⁸PLT in AF patients, potentially influenced by factors such as AF type, smoking status, 489 and geographic region⁴². We found no causal associations between the remaining trait 490 pairs, and the limited causal evidence suggests that the BCTs-CVDs trait pair

491 associations are less driven by causality and may be primarily mediated by horizontal

493

⁴⁹⁴Although we discovered that BCTs and CVDs share a common genetic foundation, it 495 remains unclear whether the association between them occurs via horizontal or 496 vertical pleiotropy. We first investigated the horizontal pleiotropy level and identified ⁴⁹⁷multiple pleiotropic loci associated with BCTs and CVDs, among which important 498 loci such as $9q34.2$, $12q24.31$, and $12q24.12$ affected more than 50% of the trait pairs. 499 Recent research has underscored the pleiotropic effects of genes within the 12q24.12 500 region on CVDs⁴³. Notably, the gene $ALDH2$, encoding aldehyde dehydrogenase 2, is 501 associated with CAD, blood pressure regulation, and alcohol-induced cardiac 502. dysfunction⁴⁴. This enzyme is essential for metabolizing both endogenous and ⁵⁰³exogenous aldehydes; its dysfunction leads to aldehyde accumulation, markedly 504 increasing the risk of specific CVDs. Furthermore, *ALDH2* modulates ⁵⁰⁵atherosclerosis-related risk factors such as foam cell formation and macrophage 506 effervescence through non-enzymatic pathways⁴⁵. Another critical gene in this region, ⁵⁰⁷*SH2B3* (also known as lymphocyte adaptor protein or *LNK*), regulates cytokine signaling and cell proliferation⁴⁶. In mouse models, targeted deletion of *LNK* disrupts 509 the negative feedback regulation of various pathways, affecting hematopoiesis and 510 enhancing thrombopoietin (TPO) signaling⁴⁷. This disruption leads to increased 511 thrombosis and atherosclerosis, thereby elevating the incidence of CVD events. 512 Consistently, studies have linked the *LNK* rs3184504 (T allele, *R262W*) variant with 513 an increased risk of CAD and thrombotic stroke⁴⁸. HyPrColoc results confirm that 514 rs3184504 is a common pathogenic variant across CAD, VTE, and 19 other BCTs, 515 highlighting the pleiotropic role of *SH2B3*. The gene *MAPKAPK5*, which encodes the ⁵¹⁶MK5 protein—a serine/threonine kinase—also shows high expression levels in the 517 human heart⁴⁹. MK5 plays a role in endothelial cell migration and angiogenesis⁵⁰ and 518 influences erythrocytes' structure, metabolism, and ion channels⁵¹, thus affecting 519 susceptibility to atherosclerosis⁵². In conclusion, the identified pleiotropic loci

520 associated with BCTs and CVDs reveal a strong genetic interrelation between these

521 traits, providing deeper insights into their complex genetic associations.

522

⁵²³In our study, we employed two gene mapping strategies to associate candidate SNPs 524 with genes that influence both BCTs and CVDs. Specifically, among the ⁵²⁵Leukocytes-CVDs trait pairs, *ALDH2*, *MAPKAPK5*, and *ACAD10*, all located at ⁵²⁶12q24.12, were identified as significant pleiotropic genes. *ACAD10*, in particular, 527 plays a crucial role in activating mitochondrial fatty acid oxidation $(FAO)^{53}$, which is 528 pivotal in developing atherosclerosis through *NLRP3* inflammasome activation and 529 IL-4-induced macrophage polarization⁵⁴. Notably, the FAO inhibitor trimetazidine 530 effectively prevents foam cell formation from macrophages originating from 531 circulating monocytes in the arterial intima⁵⁵. About Platelets-CVDs trait pairs, ⁵³²*TNFSF12* (17p13.1) has emerged as key pleiotropic genes. SMR studies have 533 demonstrated a significant association between *TNFSF12* protein levels and PCT-AF. ⁵³⁴*TNFSF12*, also known as *TWEAK*, activates the JAK2/STAT3 pathway via the Fn14 535 receptor, inducing hypertrophy in HL-1 atrial myocytes—a vital adaptive change in 536 AF development⁵⁶. This pathway also influences PLT and vascular permeability³³. ⁵³⁷Given their potential, the drugs BIIB-023 and RO-5458640, currently indicated for ⁵³⁸lupus nephritis and rheumatoid arthritis, respectively, warrant further investigation in 539 clinical trials to evaluate their efficacy in treating PCT and AF. Regarding ⁵⁴⁰Erythrocytes-CVDs trait pairs, *ZNF664* and *CCDC92*, both located in the 12q24.31 541 region, are critical. *CCDC92*, a coiled-coil domain protein, is intimately associated 542 with lipid metabolism and insulin sensitivity³⁸. Insulin resistance, influenced by ⁵⁴³*CCDC92*, leads to coronary endothelial dysfunction and promotes vascular smooth ⁵⁴⁴muscle cell proliferation via insulin-like growth factor receptors, exacerbating 545 atherosclerosis⁵⁷. At the same time, no studies have directly linked *CCDC92* with 546 erythroid characteristics; *ZNF664* and *CCDC92* exhibit co-regulated expression 547 patterns and engage in nearly identical molecular pathways^{58,59}.

548

⁵⁴⁹Shared genetic determinants indicate common biological pathways underlying

⁵⁵⁰Leukocytes-CVDs trait pairs. Our pathway analysis revealed that inflammatory 551 responses are critical, with *TNFSF12* playing a significant role. Specifically, 552 inflammatory reactions within the vessel wall, coupled with oxidative stress from 553 endothelial dysfunction, are pivotal in the progression of atherosclerosis⁶⁰. For 554 example, circulating monocytes infiltrate fatty streaks and differentiate into 555 macrophages with pro-inflammatory properties⁶¹. These macrophages then recruit 556 inflammatory factors, amplifying local inflammatory responses. A notable mediator, ⁵⁵⁷Irg1, exacerbates inflammation by promoting the formation of neutrophil extracellular 558 traps (NETs) and activating the *NLRP3* inflammasome in macrophages, enhancing 559 IL-1β release⁶². In analyzing Platelets-CVDs trait pairs, we focused on key processes 560 such as hemostasis, platelets activation, and aggregation involving *GP6*. Platelets, 561 derived from megakaryocytes, are fundamental to the pathogenesis of coronary thrombosis and atherosclerosis⁶³. Peptide hormone receptors on platelets may trigger thrombosis⁶⁴, while the chemokines they secrete play roles in both inflammation and 564 hemostasis⁶⁵. Additionally, oxidative stress and the production of reactive oxygen 565 species (ROS) activate platelets, profoundly affecting CVD pathogenesis, especially 566 in older individuals. Regarding Erythrocytes-CVDs trait pairs, pathways involved in 567 vascular development and the circulatory system are crucial, with *TNFSF12* also ⁵⁶⁸implicated. Erythrocytes primarily influence blood viscosity, impacting the friction 569 exerted on the arterial wall, a key factor in maintaining systemic arterial pressure 570 post-birth and promoting vasoconstriction⁵. Pathologically, collisions of erythrocytes 571 with the arterial wall can lead to local retention and hemolysis of their membrane 572 lipids, which are associated with both the early and late stages of atherosclerosis^{66,67}. 573 From a classification perspective, our study elucidates how different pathways ⁵⁷⁴mediate the association between BCTs and CVDs, highlighting that targeted 575 regulation of key genes could significantly reduce disease risk.

576

⁵⁷⁷Using SMR and colocalization analysis, we identified three significantly shared 578 proteins—GP6, TNFSF12, and SERPINE2—across seven trait pairs. Both GP6 and ⁵⁷⁹TNFSF12 are key target proteins currently under clinical investigation. GP6 encodes

580 platelets glycoprotein VI, essential for collagen-dependent activation, signal 581 transduction, and full platelets activation, adhesion, and aggregation⁶⁸. Variants in ⁵⁸²GP6, such as the common variant rs1613662, are associated with increased VTE risk 583 and alterations in platelets function, impacting CVDs susceptibility. Although no 584 studies have reported how GP6 participates in erythrocyte physiological processes, 585 our analysis highlights that GP6 upregulation correlates with heightened VTE risk and 586 elevations in 2 platelet parameters (MPV and PDW) and 4 erythrocyte parameters 587 (HLR_P, HLR, RET_P, and RET). This suggests that the GP6 inhibitor, glenisomab, ⁵⁸⁸may represent a promising drug repurposing opportunity to mitigate excessive VTE 589 risk and elevated platelet and erythrocyte parameters. Restingly, common CVD 590 preventive drugs such as aspirin do not target the pathogenic proteins identified in our 591 SMR analysis. This may be due to the inability of blood-based cis-eQTL analysis to 592 capture anticoagulant factors produced by the liver. Moreover, the TNFSF12 inhibitor ⁵⁹³BIIB-023 could be repurposed to reduce the risk of PCT and AF complications. ⁵⁹⁴However, the underlying mechanisms remain under-explored, highlighting our 595 proposal as novel and underscoring the need for further research.

596

597 In conclusion, this is the first study to characterize the pleiotropic effects of a range of ⁵⁹⁸BCTs and CVDs on a large scale and provide important insights into the genetic 599 architecture widely distributed throughout the genome and the mechanisms behind ⁶⁰⁰common genetic diseases. These results have successively provided new clues at the 601 level of pleiotropic SNPs and genes, biological pathways, potential drug proteins, and ⁶⁰²causal relationships and will facilitate further laboratory investigations and clinical 603 studies.

604

⁶⁰⁵**Limitations of the study**

Our study presents several limitations. First, the GWAS datasets employed to investigate BCTs and CVDs may include cases with concurrent blood cell abnormalities and CVDs, potentially introducing bias into our analysis of genetic 609 overlap. Second, the lack of rare variants in most GWAS datasets restricts our ability

610 to explore pleiotropy between rare loci associated with BCTs and CVDs, which could 611 deepen our understanding of the disease mechanisms. Third, while minimizing 612 demographic bias, our focus on European populations limits our findings' 613 generalizability to other ethnic groups. Finally, the new pathway signals and gene loci 614 identified require further validation through clinical cohort studies or animal models 615 to bolster the robustness and credibility of our results.

616

⁶¹⁷**STAR**★**Methods**

⁶¹⁸**Key resources table**

REAGENT or RESOURCE IDENTIFIER Deposited data

619

⁶²⁰**Resource availability**

⁶²¹**Lead contact**

- ⁶²²Further information and requests for resources and reagents should be directed to and
- 623 will be fulfilled by the lead contact, Luke Kong (kongluke $2005@163$.com).
- 624

⁶²⁵**Materials availability**

- 626 This study did not generate new unique reagents.
- 627

⁶²⁸**Data and code availability**

⁶²⁹The study used only openly available GWAS summary statistics on blood cell traits 630 and cardiovascular diseases that have originally been conducted using human data. 631 GWAS summary statistics on BCTs are available at ⁶³²ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_trait ⁶³³s/. GWAS summary statistics on AF, HF, and Stroke are available at the GWAS ⁶³⁴Catalog (GCST90104539, GCST009541, and GCST90104539). GWAS summary 635 statistics on CAD and PAD are publicly available for download at the Cardiovascular ⁶³⁶Disease Knowledge Portal (CVDKP) website: https://cvd.hugeamp.org/datasets.html. ⁶³⁷GWAS summary statistics on VTE are obtained from the deCODE genetics website: ⁶³⁸https://www.decode.com/summarydata/. All data are publicly available and listed in 639 the key resources table. No unique datasets or code were generated for this study. Any 640 additional information required for reanalysis of the data reported in this article is 641 available from the primary contact on request. 642

⁶⁴³**Method details**

⁶⁴⁴**Study Design**

645 Figure 1 presents the workflow for this study

646

⁶⁴⁷**Data selection and quality control**

⁶⁴⁸Summary statistics for 29 BCTs were retrieved from a genome-wide association study 649 of 408,112 participants of European ancestry in the UK Biobank cohort, which 650 included data on leukocytes, platelets, and erythrocytes¹⁶. Additionally, we integrated ⁶⁵¹GWAS summary data on six major CVDs for individuals of European ancestry with 652 sample sizes exceeding 50,000 to ensure robust statistical power. Specifically, ⁶⁵³summary data for AF were derived from a large-scale meta-analysis including six ⁶⁵⁴contributing studies: the Nord-Trøndelag Health Study (HUNT), deCODE, the ⁶⁵⁵Michigan Genomics Initiative (MGI), DiscovEHR, UK Biobank, and the AFGen 656 Consortium, encompassed 60,620 cases and 970,216 controls of European ancestry⁶⁹. 657 Summary data for CAD were derived from GWAS summary statistics from a 658 genome-wide meta-analysis by the CARDIoGRAMplusC4D Consortium and UK 659 Biobank, including 181,522 cases and 984,168 controls of European ancestry⁷⁰. ⁶⁶⁰Summary data for VTE were sourced from a genome-wide association study by Jonas 661 Chouse et al., featuring 81,190 cases and 1,419,671 controls of European ancestry⁷¹. 662 Summary statistics for HF were extracted from a GWAS meta-analysis by Sonia Shah ⁶⁶³et al., including data from 47,309 cases and 930,014 controls of European ancestry ⁶⁶⁴across 26 studies from the Heart Failure Molecular Epidemiology for Therapeutic 665 Targets (HERMES) Consortium⁷². Summary statistics for PAD were obtained from a ⁶⁶⁶large-scale GWAS meta-analysis comprising 12,086 cases and 499,548 controls of 667 European ancestry⁷³. Summary statistics for stroke, involving 73,652 cases and ⁶⁶⁸1,234,808 controls of European ancestry, were retrieved from the GlGASTROKE 669 consortium⁷⁴. Detailed information on these GWAS summary statistics and their 670 original publication sources is available in Table 1.

671

⁶⁷²We implemented stringent quality control measures to ensure the integrity of our 673 GWAS summary data and facilitate a valid comparison between BCTs and CVDs. ⁶⁷⁴These included (i) aligning the data with the hg19 genome build based on the 1000 675 Genomes Project v3 Europeans reference; (ii) filtering out SNPs that either lacked a 676 reference SNP ID (rsID) or had duplicated rsIDs; (iii) excluding non-biallelic SNPs, ⁶⁷⁷which do not have precisely two allele forms; (iv) removing SNPs with a minor allele

- ⁶⁷⁸frequency (MAF) below 0.01, ensuring that only commonly occurring variants are
- 679 analyzed. Following these measures, we included only common SNPs in the analysis,
- 680 totaling $6,923,169$, available across all traits.
- 681

⁶⁸²**Statistical Analysis**

⁶⁸³**Genome-wide genetic correlations between BCTs and CVDs**

684 We used LDSC to analyze the h^2_{SNP} and r_g between 29 BCTs and 6 major CVDs. ⁶⁸⁵LDSC helps quantify the contributions of polygenic effects by examining the 686 relationship between linkage disequilibrium scores from GWAS summary results and 687 SNP test statistics⁷⁵. Initially, univariate LDSC was used to assess the SNP-based 688 heritability for each of the 29 BCTs and 6 CVDs, which measures the proportion of 689 phenotypic variance explained by common genetic variants. For this analysis, we 690 calculated LD scores using the 1000 Genomes Phase 3 European reference⁷⁶, 691 excluding variants within the major histocompatibility complex (MHC) region (CHR ⁶⁹²6: 25–35 Mb) due to its complex LD structure. We then conducted bivariate LDSC to 693 evaluate the genetic correlations among 174 BCTs and CVDs pairwise combinations. ⁶⁹⁴This step calculates the proportion of SNP-based heritability shared between two 695 traits, normalized by the geometric mean of their heritability estimates, with 696 correlation values ranging from -1 to $+1$ to indicate the direction of genetic effects. To ⁶⁹⁷adjust for multiple comparisons, we employed the FDR method, setting an FDR 698 threshold of ≤ 0.05 to determine statistical significance.

699

⁷⁰⁰We employed LDSC-SEG to explore whether the SNP heritability of 29 BCTs and 6 701 major CVDs is significantly correlated with tissue-specific gene expression, thereby 702 identifying relevant tissues⁷⁷. Utilizing multi-tissue gene expression data from the ⁷⁰³Genotype-Tissue Expression (GTEx) project and additional data from the Franke 704 laboratory, we analyzed patterns across 53 tissues and 152 cell types⁷⁸. Furthermore, ⁷⁰⁵we enhanced our validation process by incorporating chromatin-based annotations 706 linked to six epigenetic marks: DNase hypersensitivity, H3K27ac, H3K4me1, ⁷⁰⁷H3K4me3, H3K9ac, and H3K36me3. These annotations included 93 tags from the

⁷⁰⁸Encyclopedia of DNA Elements (ENCODE) project and 396 tags from the Roadmap ⁷⁰⁹Epigenomics database, which validated our analysis. To determine the statistical 710 significance of the coefficients for the identified tissues, we applied a FDR threshold 711 of 0.05.

 712

⁷¹³**Local genetic correlation analyses between BCTs and CVDs**

⁷¹⁴To investigate local genetic correlations between 29 BCTs and 6 major CVDs within 715 specific genomic regions, we utilized the LAVA. LAVA computed local- r_{g} s for 2,495 716 semi-independent genetic loci, each approximately 1 Mb in size, identified by ⁷¹⁷dividing the genome into blocks with minimal LD between them. The LD reference 718 panel, derived from the 1000 Genomes Project Phase 3 of European ancestry⁷⁶, 719 excluded the MHC region (chr6:25-35 Mb). Initial univariate tests ascertained the 720 local heritability of each trait using a stringent p-value threshold of $\langle 1 \times 10^{-4}$ to 721 exclude loci with insignificant genetic correlation or univariate heritability. ⁷²²Subsequently, we performed 80,126 bivariate tests on loci and traits that exhibited ⁷²³significant univariate genetic signals. To address the conservative nature of the 724 Bonferroni correction, we applied a FDR of 0.05 to identify significant associations.

725

⁷²⁶For regions identified by LAVA with evidence of shared risk loci across multiple phenotypes, we conducted a multi-trait co-localization analysis using $HyPrColor^{79}$. ⁷²⁸This method builds on the COLOC framework and simultaneously assesses ⁷²⁹co-localization among several traits by calculating the PP of multiple traits 730 co-localizing due to a single causal variant. A SNP with a PP exceeding 0.7 indicates a 731 significant co-localization signal, pointing to shared causal mechanisms within the 732 region.

733

⁷³⁴**Genetic overlap analysis between BCTs and CVDs**

⁷³⁵To further explore the genetic overlap between BCTs and six major CVDs, we 736 applied the GPA 80 . This method leverages GWAS summary results, using the 737 intersection of P-values for each phenotype as input, and fits a GPA model based on

738 the resulting P-value matrix data. GPA categorizes SNPs into four groups according 739 to their association with the traits: SNPs unrelated to any traits $(\pi 00)$, related only to 740 the first trait (π 10), related only to the second trait (π 01), and associated with both 741 traits $(\pi 11)$. This classification helps estimate the proportions of SNPs and elucidates 742 the causal effects on the phenotypes. The statistical significance of the genetic overlap 743 is assessed using a Likelihood Ratio Test (LRT), which tests the fit of the four-group ⁷⁴⁴model against a model of independent effects. GPA assumes P-values from null SNPs 745 follow a uniform distribution, while those from non-null SNPs follow a Beta 746 distribution. The PAR, defined as $\pi 11/(\pi 01 + \pi 10 + \pi 11)$, represents the proportion of SNPs associated with both traits relative to those associated with at least one trait⁸¹. 748 To minimize the influence of LD on our GPA estimates, we performed LD pruning 749 using PLINK 82 with genotype data from the 1000 Genomes Project Phase 3 for 750 European ancestry, selecting relatively independent $SNPs^{76}$. We then applied the FDR 751 method to correct for multiple testing, with an FDR threshold of $\langle 0.05 \rangle$ to determine 752 statistical significance.

753

⁷⁵⁴**Mendelian randomization analysis using LHCMR**

⁷⁵⁵We employed the LHC-MR method to explore potential causal relationships between 29 BCTs and 6 major CVDs⁸³. Unlike traditional polygenic MR approaches that rely 757 only on genome-wide significant SNPs, LHC-MR exploits all genome-wide variation 758 for causal estimation, using structural equation models to relate genome-wide 759 associations to traits and confounders. LHC-MR enhances the ability to estimate ⁷⁶⁰bidirectional causal effects, direct heritability, and confounding effects, as well as 761 accommodate sample overlap. Moreover, we also applied traditional bidirectional MR 762 models for sensitivity analysis, including MR Egger, weighted median, inverse variance 763 weighted (IVW), simple mode, and weighted mode⁸⁴. Estimates from LHC-MR are 764 reported as odds ratios (ORs) with corresponding 95% confidence intervals (CIs). We ⁷⁶⁵applied a Bonferroni correction to rigorously evaluate causal relationships between 766 trait pairs, setting a significance threshold at $P < 1.44 \times 10^{-4}$ (0.05 divided by 174 pairs, 767 then divided by 2 to account for testing in both directions). A unidirectional causal

- ⁷⁶⁸relationship was established when the P-value in one direction was below the
- 769 threshold, while in the opposite direction, it exceeded 0.05. Conversely, a
- ⁷⁷⁰bidirectional relationship was confirmed when the P-values in both directions were
- 771 below 1.44×10^{-4} .
- $\frac{1}{2}$

⁷⁷³**SNP-level Analysis**

⁷⁷⁴**Pleiotropic SNPs Identified by PLACO**

775 To assess the evidence for horizontal pleiotropy between 29 BCTs and 6 major CVDs, 776 we utilized the PLACO. PLACO is a sophisticated statistical method designed to ⁷⁷⁷detect pleiotropic associations of each variant by evaluating the hypothesis that a SNP 778 is associated with neither or just one of the traits⁸⁵. This hypothesis is subdivided into 779 four specific scenarios: (1) H00, indicating no association with either trait; (2) H10, 780 suggesting an association exclusively with the first trait; (3) H01, indicating an 781 association solely with the second trait; and (4) H11, representing a pleiotropic 782 association with both traits. The test statistic is calculated as the product of the Z 783 statistics for the SNPs for each trait, which is assumed to follow a mixture distribution. 784 To ensure accuracy, SNPs with squared Z statistics (Z^2) greater than 100 are excluded 785 from analysis. SNPs are declared significantly pleiotropic at the genome-wide level if 786 their *P*-values are less than 5×10^{-8} .

787

⁷⁸⁸**Genomic loci definition and functional analysis**

789 We employed the FUMA platform⁸⁶ to identify and functionally annotate independent

790 genomic loci and pleiotropic SNPs identified through PLACO. FUMA processes

⁷⁹¹GWAS summary statistics to annotate and prioritize SNPs and genes, enhancing data

792 interpretation through interactive visualizations⁷⁶. Using European population data

- 793 from the 1000 Genomes Phase 3 as a reference, we identified independently
- 794 significant SNPs ($P < 5 \times 10^{-8}$, $r^2 < 0.6$) from GWAS results. LeadSNPs were then
- 795 defined from these SNPs based on mutual independence $(r^2 < 0.1)$, and genomic risk
- 796 sites were determined where SNPs were in LD ($r^2 > 0.6$). LD blocks within lead SNPs,
- 797 separated by less than 500 kb, were combined into single sites, with the top lead SNP

798 determined by the lowest P value in each site. We then evaluated the directional 799 effects of these top SNPs by comparing Z-scores, considering them novel if 800 inconsistent with any previously reported loci for BCTs or CVDs in original GWAS. 801 For functional and pathogenic prediction of variants, we utilized ANNOVAR, ⁸⁰²applying metrics like the CADD score to predict the deleteriousness of variants based 803 on 67 functional annotations. SNPs with a CADD score over 12.37 were considered 804 harmful⁸⁷. The regulatory potential of SNPs was assessed using RegulomeDB scores, ⁸⁰⁵ranging from 1a (strong evidence of regulatory function) to 7, with lower scores 806 indicating higher activity⁸⁸. Chromatin states, predicted by ChromHMM using five 807 chromatin markers across 127 epigenomes, helped highlight the regulatory landscape 808 of genomic regions⁸⁹. Lastly, SNP-gene associations were analyzed through positional 809 mapping within a 10 kb window of genes and eQTL mapping from GTEx v8 data to 810 identify significant cis-SNP gene pairs within 1 Mb relevant to the studied traits.

811

⁸¹²**Bayesian colocalization analysis**

813 Bayesian colocalization analysis used the 'coloc' R package on pleiotropic loci 814 annotated by FUMA to identify shared causal variants within each locus⁹⁰. This ⁸¹⁵analysis assesses whether specific loci contain a causal variation that influences two 816 traits simultaneously. We tested five hypotheses using COLOC to evaluate different scenarios of genetic influence at these loci^{91} : PP0: no association with either trait; PP1: 818 a causal variant affects only the first trait; PP2: a causal variant affects only the 819 second trait; PP3: different causal variants affect each trait.; PP4: a common causal 820 variant affects both traits. Loci with a posterior probability for hypothesis four (PP.H4) 821 greater than 0.7 were deemed to exhibit significant colocalization. Within these loci, 822 the SNP showing the highest PP.H4 was identified as the putative causal variant, 823 suggesting a strong genetic link between the traits at this genomic location.

824

⁸²⁵**Gene-level Analysis**

⁸²⁶**Gene-based association analysis using MAGMA**

827 To identify candidate pleiotropic genes based on the pleiotropic SNPs identified by 828 PLACO and single-trait GWAS results, we employed the MAGMA. This analysis 829 utilizes multiple linear principal component regression to map SNP annotations from 830 GWAS data onto the genome, detecting gene-disease associations. MAGMA's 831 strength lies in aggregating evidence from multiple genetic variants within the same 832 gene to enhance the detection of novel genetic signals. For analytical robustness, we 833 restricted our analysis to protein-coding genes containing at least ten SNPs. Gene ⁸³⁴annotations were aligned with the Genome Reference Consortium Human Build 37 ⁸³⁵(hg19), and the analysis incorporated the 1000 Genomes Phase 3 European LD score 836 reference panel⁷⁶, focusing on 17,636 autosomal protein-coding genes. SNPs were ⁸³⁷systematically assigned to genes based on their location within the gene body or 838 within a ± 10 kb window surrounding the gene. Additionally, regions within the MHC ⁸³⁹(chr6:25-35 Mb) were excluded due to their complex linkage disequilibrium patterns. 840 We applied a rigorous Bonferroni correction for multiple testing across 17,636 841 protein-coding genes and 174 trait pairs, setting a stringent significance threshold for 842 the MAGMA analysis at $P < 0.05/(17,636\times174)$.

843

⁸⁴⁴**Investigation of the tissue-specific genes using EMAGMA and TWAS**

845 To overcome limitations in identifying causal genes using traditional MAGMA, 846 which assigns SNPs to genes within a genomic window, we implemented 847 E-MAGMA 92 for transcriptome-wide association analysis. This enhanced approach 848 uses tissue-specific cis-eQTL information from the GTEx v8 to link SNPs more 849 accurately with their putative genes, thereby improving the biological interpretability 850 of gene-based association analyses in BCTs and CVDs. E-MAGMA, adhering to the 851 statistical framework of MAGMA, utilizes multiple linear principal component 852 regression models. We focused our analysis on ten GTEx v8 tissues previously ⁸⁵³identified as relevant to BCTs and CVDs, including arterial, adipose, and cardiac 854 tissues. To mitigate analytical complexities, regions like the MHC (chr6:25-35 Mb) ⁸⁵⁵were excluded, and we employed Bonferroni-corrected significance thresholds 856 tailored per tissue and trait pair, ensuring robust statistical validation.

857

858 Complementing our E-MAGMA analysis, we conducted $TWAS⁹³$ using the 859 Functional Summary-based Imputation (FUSION) approach. TWAS integrates gene 860 expression data with single-trait GWAS results to uncover tissue-specific genetic 861 influences. We employed various prediction models, including Best Linear Unbiased 862 Prediction (BLUP), Least Absolute Shrinkage and Selection Operator (LASSO), ⁸⁶³Elastic Net, and Bayesian Sparse Linear Mixed Model (BSLMM), selecting the model 864 that provided the best prediction accuracy for each tissue. Adjustments for multiple ⁸⁶⁵comparisons were made using the Bonferroni method across each tissue type to 866 ensure the statistical rigor of our findings.

867

⁸⁶⁸**Pathway-level analysis using MAGMA and Metascape**

⁸⁶⁹We used MAGMA gene set analysis to elucidate the biological relevance of 870 pleiotropic genes identified from overlaps detected by MAGMA and subsequent 871 pathway enrichment annotation⁹⁴. This involved a competitive gene set enrichment 872 analysis using MAGMA, which assesses whether genes within specific sets exhibit ⁸⁷³stronger associations with the phenotype than those in other gene sets across the 874 genome. Our analysis included 9,398 gene sets from the Molecular Signatures 875 Database (MSigDB, version 2023.1), particularly focusing on the C2: Reactome 876 Pathways and C5: GO Biological Processes and various biological process sets. We 877 applied a stringent Bonferroni correction for multiple testing, setting the threshold at 878 $P = 0.05 / (7744 + 186 + 1654) / 174 = 3.00 \times 10^{-8}$ to ensure robust statistical validity.

879

880 In addition, we used Metascape to perform pathway enrichment analysis on genes 881 significantly identified in MAGMA and E-MAGMA analyses to elucidate the ⁸⁸²biological functions and pathways of pleiotropic genes associated with BCTs and 883 \cdot CVDs. Metascape⁹⁵ integrates functional enrichment analysis, interaction analysis, ⁸⁸⁴gene annotation, and member search functions to facilitate comprehensive ⁸⁸⁵bioinformatics analysis of bulk genes. For pathway enrichment analysis, we used the 886 following ontology sources: GO annotation, KEGG, and Reactome pathways. P

887 values below 0.01 were considered statistically significant.

888

⁸⁸⁹**Proteome-wide Mendeian Randomization analysis using SMR and**

⁸⁹⁰**Colocalization analysis**

891 To explore potential common pathogenic factors at the proteomic level between 29 892 BCTs and 6 major CVDs, we employed $SMR⁹⁶$. We analyzed disease GWAS data 893 and pQTL data from the deCODE Health study and the UKB-PPP. The deCODE 894 study measured 4,719 plasma proteins in 35,559 Icelandic individuals using the 895 SomaScan platform, while the UKB-PPP assessed 2,940 proteins in 34,557 European 896 individuals using the Olink Explore platform. Instrumental variables for SMR were selected based on genome-wide significant SNPs ($P < 5 \times 10^{-8}$) located within ± 1 Mb 898 of the transcription initiation sites of target genes. SMR is a novel MR method used to ⁸⁹⁹determine the association between genetically determined traits, such as gene ⁹⁰⁰expression and plasma protein levels, and outcomes of interest, such as disease 901 phenotypes. This method integrates multi-omics data to facilitate the exploration of 902 potential causal relationships between specific drug targets and diseases. To validate 903 the observed causal associations, the HEIDI⁹⁶ test is applied; a p-value below 0.01 ⁹⁰⁴indicates the presence of linkage disequilibrium and pleiotropy. For sensitivity 905 analysis, SMR employs multi-SNP-SMR for each circulating protein, setting a 906 significance threshold at $p < 0.05$, strengthening the main analysis's evidence. The ⁹⁰⁷significance level is adjusted for multiple testing using the Bonferroni method, 908 establishing the threshold at $p < 5.23 \times 10^{-7}$ (0.05 divided by 2,730 unique proteins ⁹⁰⁹and 35 traits). We then performed Bayesian colocalization analysis to complement our ⁹¹⁰SMR findings and determine whether the same causal variants underlie the 911 associations between protein levels and disease phenotypes. A posterior probability ⁹¹²(PP.H4) greater than 0.7 indicates significant colocalization, suggesting that identical ⁹¹³genetic factors may influence protein abundance and disease outcomes concurrently.

914

⁹¹⁵To assess the therapeutic potential of the identified proteins, we utilized the 916 OpenTargets database, which compiles comprehensive data from 22 renowned

917 sources. These sources include genetic associations, somatic mutations, existing drugs, ⁹¹⁸differential expression, animal models, and insights into pathways and systems 919 biology, providing a rich foundation for identifying potential therapeutic applications. ⁹²⁰The database further enhances our analysis by categorizing protein-related drugs 921 according to their clinical trial phases, as reported on the ClinicalTrials website. ⁹²²Additionally, to ensure the reliability of our findings, we cross-referenced the 923 identified proteins against a well-curated list of druggable genes. Finally, we 924 thoroughly examined the drugs associated with these target proteins, assessing their 925 relevance and potential efficacy based on current clinical and preclinical evidence.

926

927

⁹²⁸**Declaration of interests**

929 The authors declare no competing interests.

930

⁹³¹**Acknowledgements**

932 Not applicable.

933

⁹³⁴**Author contributions**

⁹³⁵L.K., F.L., B.Z. and Y.L. conceptualized and supervised this project and wrote the 936 manuscript. L.K. and K.Y. performed the main analyses and wrote the manuscript. ⁹³⁷L.K., L.Z., Y.Z., M.C., and Z.H. performed the statistical analysis and assisted with 938 interpreting the results. Q.W. and Q.F. provided expertise in cardiovascular biology 939 and GWAS summary statistics. All authors provided intellectual content and approved 940 the final version of the manuscript.

941

⁹⁴²**References** 943 1. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, Naghavi M, Mensah GA,
944 Murray CJ. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med.
945 2. Monteiro Júnior J 946 2. Monteiro Júnior JGM, de Oliveira Cipriano Torres D, Filho DCS. Hematological Parameters as
947 Prognostic Biomarkers in Patients with Cardiovascular Diseases. Curr Cardiol Rev. 2019:15(4):274-282. 945 2015;372(14):1333-41. doi:10:1056/NEJMoa1406656
946 2. Monteiro Júnior JGM, de Oliveira Cipriano Tor
948 doi:10.2174/1573403×15666190225123544 947 Prognostic Biomarkers in Patients with Cardiovascular Diseases. Curr Cardiol Rev. 2019;15(4):274-282.
948 doi:10.2174/1573403x15666190225123544
949 3 Erostegård J. Immunity atherosclerosis and cardiovascular disease. B 947 Prognostic Biomarkers in Patients with Cardiovascular Diseases. Curr Cardiol Rev. 2019,19(4):274-202.
948 doi:10.2174/1573403x15666190225123544
949 doi:10.1186/1741-7015-11-117 949 doi:10.2174/1573403x15666156225123544
949 3. Frostegård J. Immunity, atheroscleros
950 doi:10.1186/1741-7015-11-117 949 3. Frostegård J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013;11:117.
950 doi:10.1186/1741-7015-11-117
951 doi:10.1038/nature01323 950 doi:10.1186/1741-7015-11-117
951 4. Libby P. Inflammation
952 doi:10.1038/nature01323
953 5. Michel JB. Martin-Ventura JL. 951 4. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868-74.
952 doi:10.1038/nature01323
953 5. Michel JB, Martin-Ventura JL. Red Blood Cells and Hemoglobin in Human Atherosclerosis and
954 Related Arter 954 Related Arterial Diseases. Int J Mol Sci. 2020;21(18)doi:10.3390/ijms21186756
955 6. Businaro R, Tagliani A, Buttari B, Profumo E, Ippoliti F, Di Cristofano C 953 5. Michel JD, Martin-Ventura JL. Red Blood Cells and Hemoglobin in Human Atherosclerosis and
954 Related Arterial Diseases. Int J Mol Sci. 2020;21(18)doi:10.3390/ijms21186756
955 Biganò B. Cellular and molecular player 954 Related Arterial Diseases. International Diseases. International Diseases. 2020;21(18)doi:10.3390/ijms21186756
956 Riganò R. Cellular and molecular players in the atherosclerotic plaque progres
957 2012:1262:134-41-doi 956 Riganò R. Cellular and molecular players in the atherosclerotic plaque progression. Ann N Y Acad Sci.
957 2012;1262:134-41. doi:10.1111/j.1749-6632.2012.06600.x
958 7. Lievens D, von Hundelshausen P. Platelets in ather 956 Rigano R. Cellular and molecular players in the atherosclerotic plaque progression. Ann N Y Acad Sci.
957 2012;1262:134-41. doi:10.1111/j.1749-6632.2012.06600.x
958 2011:106(5):827-38. doi:10.1160/th11-08-0592 957 2012;1202:134-41. doi:10.1111/j.1749-0092:2012.00000.x
958 7. Lievens D, von Hundelshausen P. Platelets
959 2011;106(5):827-38. doi:10.1160/th11-08-0592
960 8 Salvagno Gl. Sanchis-Gomar E. Picanza A. Linni G. B 959 2011;106(5):827-38. doi:10.1160/th11-08-0592
1960 - 8. - Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: A simple
1961 - parameter - with - multiple - clinical - applications. Crit. 959 2011;100(9):027-38. doi:10.1160/th11-08-0592
960 8. Salvagno GL, Sanchis-Gomar F, Picanza A,
961 doi:10.3109/10/08363-2014-992064 961 Barameter with multiple clinical applications. Crit Rev Clin Lab Sci. 2015;52(2):86-105.
962 doi:10.3109/10408363.2014.992064
963 9 Kannel WB Anderson K Wilson BW White blood cell count and cardiovascular disease Insig 962 doi:10.3109/10408363.2014.992064
963 9. Kannel WB, Anderson K, Wilson PW. White blood cell count and cardiovascular disease. Insights
964 from the Framingham Study. Jama. 1992:267(9):1253-6. 964 from the Framingham Study. Jama. 1992;267(9):1253-6.
965 10. Waterhouse DF. Cahill RA. Sheehan F. McCreery C. 965 10. Waterhouse DF, Cahill RA, Sheehan F, McCreery C. Prediction of calculated future cardiovascular
966 disease by monocyte count in an asymptomatic population. Vasc Health Risk Manag. 2008;4(1):177-87. 965 from the Framingham Study. Jama. 1992,267(9):1293-6.
965 follow Materhouse DF, Cahill RA, Sheehan F, McCreery C.
967 fol:10.2147/whrm 2008.04.01.177 966 disease by monocyte count in an asymptomatic population. Vasc Health Risk Manag. 2008;4(1):177-87.
967 doi:10.2147/vhrm.2008.04.01.177
968 11 Núñez L. Miñana G. Bodí V. Núñez E. Sanchis L. Husser O. Llàcer A. Low lymph 967 doi:10.2147/vhrm.2008.04.01.177
11. Núñez J, Miñana G, Bodí V, Núñez E, Sanchis J, Husser O, Llàcer A. Low lymphocyte count and
1969 - cardiovascular diseases. Curr Med Chem. 2011:18(21):3226-33. doi:10.2174/0929867117 cardiovascular diseases. Curr Med Chem. 2011;18(21):3226-33. doi:10.2174/092986711796391633
970 12. Guasti L. Dentali F. Castiglioni L. Maroni L. Marino F. Squizzato A. Ageno W. Gianni M. Gaudio 969 11. Núñez J, Miñana G, Bodí V, Núñez E, Sanchis J, Husser O, Elacer A. Low lymphocyte count and
969 12. Guasti L, Dentali F, Castiglioni L, Maroni L, Marino F, Squizzato A, Ageno W, Gianni M, Gaudio G,
971 16randi AM e eandiovascular diseases. Curr Med Chem. 2011;18(21):3228-33. doi:10.2174/092986711798391633
970 Guasti L, Dentali F, Castiglioni L, Maroni L, Marino F, Squizzato A, Ageno W, Gianni M, Gaudio
972 970 12. Guasti E, Bentali F, Castiglioni E, Maroni E, Marino F, Squizzato A, Ageno W, Gianni M, Gaudio G,
971 Grandi AM, et al. Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or
973 2011:10 971 Grandi AM, et al. Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or
972 cardiac revascularisation. A systematic review on more than 34,000 subjects. Thromb Haemost.
974 13 Havbar H. Pez 972 cardiac revascularisation. A systematic review on more than 34,000 subjects. Thromb Haemost.
973 2011;106(4):591-9. doi:10.1160/th11-02-0096
974 13. Haybar H, Pezeshki SMS, Saki N. Evaluation of complete blood count pa 973 2011;100(4):591-9. doi:10.1100/th11-02-0050
974 13. Haybar H, Pezeshki SMS, Saki N. Ev
975 doi:10.1016/iveymp.2019.104267 974 13. Haybar H, Pezeshki SMS, Saki N. Evaluation of complete blood count parameters in
976 doi:10.1016/j.yexmp.2019.104267
977 14 Williams PT Quantile-Specific Heritability of Mean Platelet Volume Leukocyte Count and Oth 976 doi:10.1016/j.yexmp.2019.104267
177 14. Williams PT. Quantile-Specific Heritability of Mean Platelet Volume, Leukocyte Count, and Other
178 Blood Cell Phenotypes. Lifestyle Genom. 2022;15(4):111-123. doi:10.1159/000527 978 Blood Cell Phenotypes. Lifestyle Genom. 2022;15(4):111-123. doi:10.1159/000527048
979 15. Lin BD. Carnero-Montoro E. Bell JT. Boomsma DI. de Geus EJ. Jansen R. Kluft 977 14. Williams PT. Quantile-Specific Heritability of Mean Platelet Volume, Leukocyte Count, and Other
978 15. Lin BD, Carnero-Montoro E, Bell JT, Boomsma DI, de Geus EJ, Jansen R, Kluft C, Mangino M,
980 – Penniny B, Spe 979 Blood Cell Phenotypes. Lifestyle Genom. 2022, 19(4):111-123. doi:10.1159/000527048
979 15. Lin BD, Carnero-Montoro E, Bell JT, Boomsma DI, de Geus EJ, Jansen R, Kluft
981 Deutrophil-to-lymphocyte and platelet-to-lympho 979 15. Lin BB, carnero-Montoro E, Bell JT, Boomsma BI, de Geus EJ, Jansen R, Klart C, Mangino M,
980 Penninx B, Spector TD, et al. 2SNP heritability and effects of genetic variants for
981 doi:10.1038/ibs 2017.76 981 Penninx B, Spector TD, et al. 2SNP heritability and effects of genetic variants for
981 neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio. J Hum Genet. 2017;62(11):979-988.
983 16 Nuckovic D Bao EL Akbari P Lar 982 doi:10.1038/jhg.2017.76
983 16. Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, Chen MH, Raffield LM, Tardaguila M,
984. Huffman, JE, et al. The Polygenic and Monogenic Basis of Blood Traits and Diseases. C 983 16. Vuckovic D, Bao EL,
984 Huffman JE, et al. The
985 2020:182(5):1214-1231. 983 16. Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, Chen MH, Raffield LM, Tardaguila M,
984 Huffman JE, et al. The Polygenic and Monogenic Basis of Blood Traits and Diseases. Cell.
985 2020:182(5):1214-1231 2020;182(5):1214-1231.e11. doi:10.1016/j.cell.2020.08.008 985 2020;182(5):1214-1231.e11. doi:10.1016/j.cell.2020.08.008

986 17. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, Mead D, Bouman H, Riveros-Mckay F,
987 Kostadima MA, et al. The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common
988 Complex Diseas 1988 Complex Disease. Cell. 2016;167(5):1415-1429.e19. doi:10.1016/j.cell.2016.10.042
18. In The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common
18. In The Allel Traition and Line Cell Traitions w

989 Complex Bisease. Cell. 2016;167(5):1415-1429.e19. doi:10.1016);cell.2016.10.042
989 18. Zhang X, Johnson AD, Hendricks AE, Hwang SJ, Tanriverdi K, Ganesh SK, Sn
991 for atheroscleratic cardiovascular disease and blood 989 18. Zhang X, Johnson AD, Hendricks AD, Hwang SJ, Tanriverdi K, Ganesh SK, Smith NC, Peyser PA,
990 Freedman JE, O'Donnell CJ. Genetic associations with expression for genes implicated in GWAS studies
991 doi:10.1093/hm 990 Freedman JE, O'Donnell CJ. Genetic associations with expression for genes implicated in GWAS studies
991 for atherosclerotic cardiovascular disease and blood phenotypes. Hum Mol Genet. 2014;23(3):782-95.
993 19 Paab 991 for atherosclerotic cardiovascular disease and blood phenotypes. Hum Mol Genet. 2014;23(3):782-95.
992 doi:10.1093/hmg/ddt461
993 19. Paaby AB, Rockman MV. The many faces of pleiotropy. Trends Genet. 2013;29(2):66-73.

994 doi:10.1016/j.tig.2012.10.010
995 20. Harshfield EL. Sims MC.

993 19. Paaby AB, Rockman MV. The many faces of pleiotropy. Trends Genet. 2013,29(2):66-73.
995 20. Harshfield EL, Sims MC, Traylor M, Ouwehand WH, Markus HS. The role of haematological traits
996 in risk of ischaemic stro 995 20. Harshfield EL, Sims MC, 1
996 in risk of ischaemic stroke and
997 21 He L Jiang O, Yao Y, S

996 in risk of ischaemic stroke and its subtypes. Brain. 2020;143(1):210-221. doi:10.1093/brain/awz362
1997 21. He J, Jiang Q, Yao Y, Shen Y, Li J, Yang J, Ma R, Zhang N, Liu C. Blood Cells and Venous
1998 1hromboembolism 997 21. He J, Jiang Q, Yao Y, Shen Y, Li J, Yang J, Ma R, Zhang N, Liu C. Blood Cells and Vend
998 Thromboembolism Risk: A Two-Sample Mendelian Randomization Study. Front Cardiovasc M
998 2022:9:919640 doi:10.3389/form 202 998 Thromboembolism Risk: A Two-Sample Mendelian Randomization Study. Front Cardiovasc Med.
999 2022;9:919640.doi:10.3389/fcvm.2022.919640
000 22. Yang Y Zhou Y Nybolt DR Yan CY Tannenberg RK Wang Y Wu Y Zhu Z Taylor RV Gr

999 11 2022;9:919640. doi:10.3389/fcvm.2022.919640
000 22. Yang Y, Zhou Y, Nyholt DR, Yap CX, Tannenberg RK, Wang Y, Wu Y, Zhu Z, Taylor BV, Gratten J. The
001 shared genetic landscape of blood cell traits and risk of neur 9999 2022, 9:919640. doi:10.3389/fcvm.2022.919640
000 22. Yang Y, Zhou Y, Nyholt DR, Yap CX, Tannenk
001 6enom 2023:3(2):100249. doi:10.1016/i yaen 2 22. Yang Y, Zhou Y, Nyholt DR, Yap CX, Tannenberg RK, Wang Y, Wu Y, Zhu Z, Taylor BV, Gratten J. The
1001 shared genetic landscape of blood cell traits and risk of neurological and psychiatric disorders. Cell
1002 Genom. 2

1001 shared genetic landscape of blood cell traits and risk of neurological and psychiatric disorders. Cell
1003 23. den Harder AM, de Jong PA, de Groot MCH, Wolterink JM, Budde RPJ, lŝgum I, van Solinge WW,
1004 - Ten Ber 1002 Genom. 2023,3(2):100249. doi:10.10107j.xgen.2022.100249
1003 23. den Harder AM, de Jong PA, de Groot MCH, Wolterink
1005 associated with the extent of coronary calcification 1004 Ten Berg MJ, Lutgens E, Veldhuis WB, et al. Commonly available hematological biomarkers are
1005 associated with the extent of coronary calcifications. Atherosclerosis. 2018;275:166-173.
1006 doi:10.1016/j.atheroscler 1005 associated with the extent of coronary calcifications. Atherosclerosis. 2018;275:166-173.
1006 doi:10.1016/j.atherosclerosis.2018.06.017
1007 24. Nikpay-M,-Mohammadzadeh-S.-Phenome-wide-screening-for-traits-causally-a

1005 associated with the extent of colonary calcifications. Atherosclerosis. 2016,275:166-175.
1006 doi:10.1016/j.atherosclerosis.2018.06.017
1008 risk of coronary attery disease. Hum Genet 2020:65(4):371-380 doi:10.1038/s 1006 doi:10.1010/j.atherosclerosis.2018.00.017
1007 24. Nikpay M, Mohammadzadeh S. Phen
1009 25. Ellingsen TS. Lannegård L. Skielbakke

1008 risk of coronary artery disease. J Hum Genet. 2020;65(4):371-380. doi:10.1038/s10038-019-0716-z
1009 25. Ellingsen TS, Lappegård J, Skjelbakken T, Brækkan SK, Hansen JB. Red cell distribution width is
1010 - associate 1009 13K of coronary artery alsease. J Hum Genet. 2020, 00(4):371-300. doi:10.1030/310038-019-0716-2
1009 25. Ellingsen TS, Lappegård J, Skjelbakken T, Brækkan SK, Hansen JB. Red cell distribution widt
1011 - population Th 1010 associated with incident venous thromboembolism (VTE) and case-fatality after VTE in a general
1011 population. Thromb Haemost. 2015;113(1):193-200. doi:10.1160/th14-04-0335
1012 26 Bucciatelli P Maino A Felicetta L A

1011 population. Thromb Haemost. 2015;113(1):193-200. doi:10.1160/th14-04-0335
1012 26. Bucciarelli P, Maino A, Felicetta I, Abbattista M, Passamonti SM, Artoni A, Martinelli I. Association
1013 between red cell distributi 1011 population. Thromb Haemost. 2015,113(1):153-200. doi:10.1160/th14-04-0335
1012 26. Bucciarelli P, Maino A, Felicetta I, Abbattista M, Passamonti SM, Artoni A, N
1013 between red cell distribution width and risk of ven 1012 26. Bucciarelli P, Maino A, Felicetta I, Abbattista M, Passamonti SM, Artoni A, Martinelli I. Association
1013 between red cell distribution width and risk of venous thromboembolism. Thromb Res.
1015 27 Varga-Szabo D

1014 between red cell distribution width and risk of venous thromboembolism. Thromb Res.
1014 2015;136(3):590-4. doi:10.1016/j.thromres.2015.07.020
1015 Thromb Vasc Biol 2008:28(3):403-12 doi:10.1161/atybaba.107.150474 2015;136(3):390-4. doi:10:1016);thromes.2015.07.020
1015 27. Varga-Szabo D, Pleines I, Nieswandt B. Cell adh
1016 Thromb Vasc Biol. 2008;28(3):403-12. doi:10.1161/atvba
1017 28. Hansen M. Zeddies S. Meinders M. di Summa E 21015 27. Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler
1016 Thromb Vasc Biol. 2008;28(3):403-12. doi:10.1161/atvbaha.107.150474
1017 28. Hansen M, Zeddies S, Meinders M, di Sum

1017 28. Hansen M, Zeddies S, Meinders M, di Summa F, van Alphen FI
1018 Halbach M, Gutiérrez L, van den Biggelaar M, et al. The RNA-Binding
1019 - during Megakanyonojesis, and May Control Timing of Gene 1017 28. Hansen M, Zeddies S, Meinders M, di Summa F, van Alphen FPJ, Hoogendijk AJ, Moore KS,
1018 Halbach M, Gutiérrez L, van den Biggelaar M, et al. The RNA-Binding Protein ATXN2 is Expressed
1019 - 2020:21(3)doi:10.339 1019 during Megakaryopoiesis and May Control Timing of Gene Expression. Int J Mol Sci.
1020 2020;21(3)doi:10.3390/ijms21030967
1021 29. Nemkov T, Stephenson D, Erickson C, Dzieciatko

1020 during Megakaryopoiesis and May Control Timing of Gene Expression. Int J Mol Sci.
1021 29. Nemkov T, Stephenson D, Erickson C, Dzieciatkowska M, Key A, Moore A, Earley EJ, Page GP,
1022 Lacroix IS Stone M et al Begula 1020 2020,21(3)doi:10.3390/ijms21030967
1021 29. Nemkov T, Stephenson D, Ericks
1022 Lacroix IS, Stone M, et al. Regulation 1022 Lacroix IS, Stone M, et al. Regulation of kynurenine metabolism by blood donor genetics and biology
1023 impacts red cell hemolysis in vitro and in vivo. Blood. 2024;143(5):456-472.
1024 doi:10.1182/blood.2023022052 1022 Lacroix IS, Stone M, et al. Regulation of kynurenine metabolism by blood donor genetics and biology
1024 doi:10.1182/blood.2023022052
1025 – 30 Ganesh SK Tragante V Guo W Guo Y Janktree MB Smith EN Johnson T Castillo

1023 impacts red cell hemolysis in vitro and in vivo. Blood. 2024,143(5):456-472.
1025 30. Ganesh SK, Tragante V, Guo W, Guo Y, Lanktree MB, Smith EN, Johnson T, Castillo BA, Barnard J,
1026 Baumert Let al Loci influencing 1025 doi:10.1182/blood.2023022032
1025 30. Ganesh SK, Tragante V, Gue
1027 Hum Mol Genet 2013:22(8):166 30. Ganesh SK, Tragante V, Guo W, Guo Y, Lanktree MB, Smith EN, Johnson T, Castillo BA, Barnard J,
1026 Baumert J, et al. Loci influencing blood pressure identified using a cardiovascular gene-centric array.
1027 Hum Mol G

1027 Baumert J, et al. Loci influencing blood pressure identified using a cardiovascular gene-centric array.
1028 31. Paterson AD, Lopes-Virella MF, Waggott D, Boright AP, Hosseini SM, Carter RE, Shen E, Mirea L,
1029 Bhaz 1027 Hum Mol Genet. 2013;22(0):1663-78. doi:10.1033/hmg/dds333
1028 31. Paterson AD, Lopes-Virella MF, Waggott D, Boright AP, Hos
1029 Bharaj B, Sun L, et al. Genome-wide association identifies the 1029 Bharaj B, Sun L, et al. Genome-wide association identifies the ABO blood group as a major locus 1029 Bharaj B, Sun L, et al. Genome-wide association identifies the ABO blood group as a major locus

associated with serum levels of soluble E-selectin. Arterioscler Thromb Vasc Biol. 2009;29(11):1958-67.
1031 doi:10.1161/atvbaha.109.192971
1032 32. Prugger C, Luc G, Haas B, Morange PE, Ferrieres J, Amouyel P, Kee F, Duci 1031 doi:10.1161/atvbaha.109.192971
1032 32. Prugger C, Luc G, Haas B, M
1033 Multiple biomarkers for the predi 1032 32. Prugger C, Luc G, Haas B, Morange PE, Ferrieres J, Amouyel I, Ree I, Buchneiere I, Empana JI.
1033 Multiple biomarkers for the prediction of ischemic stroke: the PRIME study. Arterioscler Thromb Vasc
1035 33 Mande

1034 Biol. 2013;33(3):659-66. doi:10.1161/atvbaha.112.300109
1035 33. Mendez-Barbero N, Yuste-Montalvo A, Nuñez-Borque E, Jensen BM, Gutiérrez-Muñoz C,
1036 - Tome-Amat J. Garrido-Arandia M. Díaz-Perales A. Ballesteros-Mar 1034 Biol. 2013;33(3):659-66. doi:10.1161/atvbaha.112.300109
1035 33. Mendez-Barbero N, Yuste-Montalvo A, Nuñez-Boi
1037 week inducer of the apoptosis (fibroblest growth fector ind 1035 33. Mendez-Barbero N, Yuste-Montalvo A, Nuñez-Borque E, Jensen BM, Gutiérrez-Muñoz C,
1036 Tome-Amat J, Garrido-Arandia M, Díaz-Perales A, Ballesteros-Martinez C, Laguna JJ, et al. The TNF-like
1037 weak inducer of th 1037 Tome-Amat J, Garrido-Arandia M, Díaz-Perales A, Ballesteros-Martinez C, Laguna JJ, et al. The TNF-like
1037 weak inducer of the apoptosis/fibroblast growth factor-inducible molecule 14 axis mediates histamine
1038 Cli 1037 weak inducer of the apoptosis) inflomate growth factor-inducible molecule 14 axis mediates instantine
1039 clin Immunol. 2020;145(2):583-596.e6. doi:10.1016/j.jaci.2019.09.019
1040 34 Eranchini M. Linni G. Belative Bi

1039 clin Immunol. 2020;145(2):583-596.e6. doi:10.1016/j.jaci.2019.09.019
1040 34. Franchini M, Lippi G. Relative Risks of Thrombosis and Bleeding in Different ABO Blood Groups.
1041 Semin Thromb Hemost. 2016;42(2):112-7 1041 Semin Thromb Hemost. 2016;42(2):112-7. doi:10.1055/s-0035-1564832
1042 35. Lee JY, Lee BS, Shin DJ, Woo Park K, Shin YA, Joong Kim K, Heo L,

1040 34. Franchin M, Lippi G. Relative Risks of Thrombosis and Bleeding in Different ABO Blood Groups.
1041 Semin Thromb Hemost. 2016;42(2):112-7. doi:10.1055/s-0035-1564832
1043 Kim Y et al. A genome wide association stud 1041 Semin Thromb Hemost. 2010, 42(2): 112-7. doi:10.1055/s-0035-1564832
1042 35. Lee JY, Lee BS, Shin DJ, Woo Park K, Shin YA, Joong Kim K, Heo L, '
1043 Kim Y, et al. A genome-wide association study of a coronary artery 1043 Kim Y, et al. A genome-wide association study of a coronary artery disease risk variant. J Hum Genet.
1044 2013;58(3):120-6. doi:10.1038/jhg.2012.124
1045 36. Méndez-Barbero N, Gutiérrez-Muñoz C,

1043 Kim I, et al. A genome-wide association study of a coronary artery disease risk variant. J Hum Genet.
1044 2013;58(3):120-6. doi:10.1038/jhg.2012.124
1045 Tumor Necrosis Eastor-Like Weak Inducer of Apontosis (TWEAK)/F 1044 2013;38(3):120-6. doi:10.1030/jhg.2012.124
1045 36. Méndez-Barbero N, Gutiérrez-Muñoz C
1047 - 14. (En14) Avis in Cardiovascular 1046 Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK)/Fibroblast Growth Factor-Inducible
1047 14 (Fn14) Axis in Cardiovascular Diseases: Progress and Challenges. Cells.
1048 1046 Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK)/Fibroblast Growth Factor-Inducible
1047 14 (Fn14) Axis in Cardiovascular Diseases: Progress and Challenges. Cells.
1049 37 Nagai M. Hirayama K. Ebibara L. H

1047 14 (FILE) Axis in Cardiovascular Diseases. Progress and Challenges. Cells.
1048 2020;9(2)doi:10.3390/cells9020405
1050 Ogawa Y Eulita S et al. Serum TNE-related and weak inducer of apoptosis levels in sentic shock. 1048 2020, 2100.10.3390/cells9020409
1049 37. Nagai M, Hirayama K, Ebihara
1051 - patients Ther Apher Dial 2011:15/4 1049 37. Nagai M, Hirayama K, Ebihara I, Higuchi T, Imaizumi M, Maruyama H, Miyamoto Y, Kakita T, 1050 Ogawa Y, Fujita S, et al. Serum TNF-related and weak inducer of apoptosis levels in septic shock
1051 patien

1052 38. Chasman DI, Paré G, Mora S, Hopewell JC, Peloso G, Clarke R, Cupples LA, Hamsten A, Kathiresan
1053 S, Mälarstig A, et al. Forty-three loci associated with plasma lipoprotein size, concentration, and patients. Ther Apher Dial. 2011;15(4):342-8. doi:10.11111);1744-9987.2011.00966.x
1052 38. Chasman DI, Paré G, Mora S, Hopewell JC, Peloso G, Clarke R, Cupples LA, Ham
1053 5, Mälarstig A, et al. Forty-three loci associate 1052 38. Chasman DI, Paré G, Mora S, Hopewell Jc, Peloso G, Clarke R, Cupples LA, Hamsten A, Rathiresan
1053 S, Mälarstig A, et al. Forty-three loci associated with plasma lipoprotein size, concentration, and
1054 doi:10.1 1053 S, Malarstig A, et al. Forty-three loci associated with plasma lipoprotein size, concentration, and
1054 cholesterol content in genome-wide analysis. PLoS Genet. 2009;5(11):e1000730.
1056 39 Ben L Du W Song D Lu H Ham

1054 cholesterol content in genome-wide analysis. TEOS Genet. 2005,5(11):e1000730.
1056 39. Ren L, Du W, Song D, Lu H, Hamblin MH, Wang C, Du C, Fan GC, Becker RC, Fan Y. Genetic ablation
1057 of diabates-associated gane C 1055 doi:10:1371/journal.pgen.1000730
1056 39. Ren L, Du W, Song D, Lu H, Har
1058 2023:26(1):105769 doi:10.1016(i.is 1056 39. Ren L, Du W, Song D, Lu H, Hamblin MH, Wang C, Du C, Fan GC, Becker RC, Fan Y. Genetic ablation
1057 of diabetes-associated gene Ccdc92 reduces obesity and insulin resistance in mice. iScience.
1058 2023;26(1):105

1057 of diabetes-associated gene Ccdc92 reduces obesity and insulin resistance in mice. iScience.
1058 2023;26(1):105769. doi:10.1016/j.isci.2022.105769
1060 associated with future risk of venous thromboembolism. Blood Adv 1058 2023;26(1):103769. doi:10:10167);lisci.2022.103769
1059 40. Ellingsen TS, Lappegård J, Ueland T, Aukrust
1061 doi:10.1182/bloodadvances.2018018465 1060 – associated with future risk of venous thromboembolism. Blood Adv. 2018;2(11):1191-1197.
1061 – doi:10.1182/bloodadvances.2018018465
1062 – 41. Luo J, Thomassen JQ, Nordestgaard BG, Tybjærg-Hansen A, Frikke-Schmidt R

1060 associated with future fisk of venous thromboembolism. Blood Adv. 2018;2(11):1191-1197.
1061 doi:10.1182/bloodadvances.2018018465
1063 and cardiovascular disease Fur Heart L2023:44(47):4953-4964 doi:10.1093/euthearti/ 1061 doi:10.1102/bloodadvances.2018010403
1062 41. Luo J, Thomassen JQ, Nordestgaard
1064 42. Weymann A Ali-Hasan-Al-Saegh S

1063 and cardiovascular disease. Eur Heart J. 2023;44(47):4953-4964. doi:10.1093/eurheartj/ehad649
1064 42. Weymann A, Ali-Hasan-Al-Saegh S, Sabashnikov A, Popov AF, Mirhosseini SJ, Nombela-Franco L,
1065 Testa L, Lot 1065 Testa L, Lotfaliani M, Zeriouh M, Liu T, et al. Platelets Cellular and Functional Characteristics in Patients
1066 with Atrial Fibrillation: A Comprehensive Meta-Analysis and Systematic Review. Med Sci Monit Basic 1065 Testa L, Lotfaliani M, Zeriouh M, Liu T, et al. Platelets Cellular and Functional Characteristics in Patients
1066 with Atrial Fibrillation: A Comprehensive Meta-Analysis and Systematic Review. Med Sci Monit Basic
106 1066 Testa L, Lottaliani M, Zeriouh M, Liu T, et al. Platelets Cellular and Functional Characteristics in Futents
1066 With Atrial Fibrillation: A Comprehensive Meta-Analysis and Systematic Review. Med Sci Monit Basic
1068

1067 Res. 2017;23:58-86. doi:10.12659/msmbr.902557
1068 43. Kim YK, Hwang MY, Kim YJ, Moon S, Han S, Kim BJ. Evaluation of pleiotropic effects among
1069 common genetic loci identified for cardio-metabo 1067 Res. 2017;23:58-86. doi:10.126597/msmbr.902557
1068 43. Kim YK, Hwang MY, Kim YJ, Moon S, Han
1069 - 2016:15:20 doi:10.1186/s12933-016-0337-1 1069 43. Kim YK, Hwang MY, Kim JJ, Moon 3, Han 3, Kim BJ. Evaluation of pleiotropic effects among
1069 common genetic loci identified for cardio-metabolic traits in a Korean population. Cardiovasc Diabetol.
1071 - 44 - Kat 1070 common genetic loci identified for cardio-metabolic traits in a Korean population. Cardiovasc Diabetol.
1071 44. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, Tay WT, Chen CH, Zhang Y, Yamamoto K, et al.
1072

1070 2010,15:20. doi:10.1100,312555-010-0557-1
1071 44. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go
1073 - pressure variation in east Asians, Nat Genet 1071 44. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, Tay WT, Chen CH, Zhang Y, Yamamoto K, et al.
1072 Meta-analysis of genome-wide association studies identifies common variants associated with blood
1073 pressu

pressure variation in east Asians. Nat Genet. 2011;43(6):531-8. doi:10.1038/ng.834 pressure variation in east Asians. Nat Genet. 2011;43(6):531-8. doi:10.1038/ng.834

1074 45. Zhang J, Guo Y, Zhao X, Pang J, Pan C, Wang J, Wei S, Yu X, Zhang C, Chen Y, et al. The role of 1075 aldehyde dehydrogenase 2 in cardiovascular disease. Nat Rev Cardiol. 2023;20(7):495-509.
1076 doi:10.1038/s41569 1075 aldehyde dehydrogenase 2 in cardiovascular disease. Nat Rev Cardiol. 2023,20(7):495-509.
1075 - 46. Wang W, Tang Y, Wang Y, Tascau L, Balcerek J, Tong W, Levine RL, Welch C, Tall AR, Wang N.
1078 - LNK/SH2B3 - Loss of 1077 46. Wang W, Tang Y, Wang Y, Tang 1078 LNK/SH2B3 Loss of Function Promotes Atherosclerosis and Thrombosis. Circ Res.
1079 2016;119(6):e91-e103.doi:10.1161/circresaha.116.308955
1080 47. Bersenev A. Wu C. Balcerek J. Tong W. Lnk controls mouse hematopoietic 1079 2016;119(6):e91-e103. doi:10.1161/circresaha.116.308955
1080 47. Bersenev A, Wu C, Balcerek J, Tong W. Lnk controls mouse hematopoietic stem cell self-renewal
1081 and quiescence through direct interactions with JAK2, 1079 2016;119(6):e91-e109. doi:10.1161/circesaha.116.306999
1080 47. Bersenev A, Wu C, Balcerek J, Tong W. Lnk controls m
1081 doi:10.1172/ici35808 1081 - and quiescence through direct interactions with JAK2. J Clin Invest. 2008;118(8):2832-44.
1082 - doi:10.1172/jci35808
1083 - 48. Deloukas P. Kanoni S. Willenborg C. Farrall M. Assimes TL. Thompson JR. Ingelsson E. S 1081 and quiescence through direct interactions with JAK2. J Clin Invest. 2006,118(0):2832-44.
1083 48. Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, Ingelsson E, Saleheen D,
1084 Erdmann L Goldst 1082 doi:10:11727jci33808
1083 48. Deloukas P, Kanc
1085 artery disease Nat Ge 1084 Erdmann J, Goldstein BA, et al. Large-scale association analysis identifies new risk loci for coronary
1085 artery disease. Nat Genet. 2013;45(1):25-33. doi:10.1038/ng.2480
1086 49. Sahadevan P, Allen BG. MK5: A nove 1085 Erdmann J, Goldstein BA, et al. Large-scale association analysis identifies new risk loci for coronary
1085 artery disease. Nat Genet. 2013;45(1):25-33. doi:10.1038/ng.2480
1085 - 2017:69(10):795-794. doi:10.1002/jub. 1085 artery disease. Nat Genet. 2013;45(1):25-33. doi:10.1030/ng.2480
1086 49. Sahadevan P, Allen BG. MK5: A novel regulator of cardia
1088 50. Voshizuka N Chen BM Xu Z Liao B. Hong L Hu WY Yu G. Han 1087 2017;69(10):785-794. doi:10.1002/iub.1677
1088 50. Yoshizuka N, Chen RM, Xu Z, Liao R, Hong L, Hu WY, Yu G, Han J, Chen L, Sun P. A novel function of
1089 - p38-regulated (activated kinase in endothelial cell migratio 1087 2017;09(10):785-794. doi:10.1002/iub.1677
1088 50. Yoshizuka N, Chen RM, Xu Z, Liao R, Hor
1089 2012:32/3}:606-18 doi:10.1128/mch 06301 1088 50. Yoshizuka N, Chen RM, Xu Z, Liao R, Hong L, Hu WY, Yu G, Han J, Chen L, Sun P. A novel function of
1089 p38-regulated/activated kinase in endothelial cell migration and tumor angiogenesis. Mol Cell Biol.
1090 2012 pse regulated activated kinase in endothelial cell migration and tumor angiogenesis. Mor cell Biol.
1090 2012;32(3):606-18. doi:10.1128/mcb.06301-11
1092 - al-Multiple ancestry genome wide association study identifies 27 l 1090 2012;32(3):606-16. doi:10.1128/mcb.06301-11
1091 51. Page GP, Kanias T, Guo YJ, Lanteri MC, Zha
1093 hemolysis following blood storage. I Clin Invest 1092 al. Multiple-ancestry genome-wide association study identifies 27 loci associated with measures of
1093 hemolysis following blood storage. J Clin Invest. 2021;131(13)doi:10.1172/jci146077
1094 52. Erbilgin A, Civelek 1094 - 52. Erbilgin A, Civelek M, Romanoski CE, Pan C, Hagopian R, Berliner JA, Lusis AJ. Identification of
1095 - CAD candidate genes in GWAS loci and their expression in vascular cells. J Lipid Res. 1093 hemorysis following blood storage. J Clin Invest. 2021;131(13)doi:10.1172/jci146077
1094 52. Erbilgin A, Civelek M, Romanoski CE, Pan C, Hagopian R, Berliner JA, Lusis AJ
1095 2013:54(7):1894-905 doi:10.1194/ilr M0370 1094 52. Erbilgin A, Civelek M, Romanoski CE, Pan C, Hagopian R, Berliner JA, Edsis AJ. Romincation of
1095 CAD candidate genes in GWAS loci and their expression in vascular cells. J Lipid Res.
1097 53 He M Pei 7 Mobsen AW 1095 CAD candidate genes in GWAS loci and their expression in vascular cells. J Lipid Res.
1096 2013;54(7):1894-905. doi:10.1194/jlr.M037085
1098 Identification and characterization of new long chain acyl CoA debydrogenaes 1097 53. He M, Pei Z, Mohsen AW, Watkins P, Mu
1098 Identification and characterization of new long
1098 2011:102(4):418-29 doi:10.1016/j.ymgme.2010 53. He M, Pei Z, Mohsen AW, Watkins P, Murdoch G, Van Veldhoven PP, Ensenauer R, Vockley J.
1098 Identification and characterization of new long chain acyl-CoA dehydrogenases. Mol Genet Metab.
1099 2011;102(4):418-29. doi: 1099 Identification and characterization of new long chain acyl-CoA dehydrogenases. Mol Genet Metab.
1009 2011;102(4):418-29. doi:10.1016/j.ymgme.2010.12.005
1101 fatty acid oxidation in atherosclerosis. Biomed Pharmacothe 2011;102(4):410-29. doi:10.1016/j.ymgme.2010.12.009
1100 54. Xiao S, Qi M, Zhou Q, Gong H, Wei D, Wang G, Fer
1101 fatty acid oxidation in atherosclerosis. Bi 1101 fatty acid oxidation in atherosclerosis. Biomed Pharmacother. 2024;170:116092.
1102 doi:10.1016/j.biopha.2023.116092
1103 55 Lennänen O Biörnheden J Evaldsson M Borén L Wiklund O Levin M ATP denlation in 1101 Fatty acid oxidation in atheroscienosis. Biomed Pharmacother. 2024;170:116092.
1103 55. Leppänen O, Björnheden T, Evaldsson M, Borén J, Wiklund O, Levin M. ATP depletion in
1104 – macrophages in the core of advanced r 1102 doi:10:10107,500pha.2023.116032
1103 55. Leppänen O, Björnheden T,
1105 2006:188(2):323-30 doi:10.1016/j 55. Leppänen O, Björnheden T, Evaldsson M, Borén J, Wiklund O, Levin M. ATP depletion in
1104 – macrophages in the core of advanced rabbit atherosclerotic plaques in vivo. Atherosclerosis.
1105 – 2006;188(2):323-30. doi:10 1106 56. Hao L, Ren M, Rong B, Xie F, Lin MJ, Zhao YC, Yue X, Han WQ, Zhong JQ. TWEAK/Fn14 mediates
1107 atrial-derived HL-1 mvocvtes hvpertrophv via JAK2/STAT3 signalling pathwav. J Cell Mol Med. 1105 2006,100(2):323-30. doi:10.1016),latherosclerosis.2005.11.017
1106 56. Hao L, Ren M, Rong B, Xie F, Lin MJ, Zhao YC, Yue X, Han
1108 - 2018:22(9):4344-4353-doi:10.1111/j.cmm 13724 1106 56. Hao L, Ren M, Rong B, Xie F, Lin MJ, Zhao Tc, Tae X, Han WQ, Zhong JQ. TWEAK/FH14 mediates
1108 atrial-derived HL-1 myocytes hypertrophy via JAK2/STAT3 signalling pathway. J Cell Mol Med.
1109 57 Jaque J, Matsunag 1107 atrial-derived HL-1 myocytes hypertrophy via JAK2/STAT3 signalling pathway. J Cell Mol Med.
1108 2018;22(9):4344-4353. doi:10.1111/jcmm.13724
1110 andothelium-dependent acetylcholine-induced coronary affery response. 1108 2010,22(9):4344-4353. doi:10.11111/jcmm.13724-
1109 57. Inoue T, Matsunaga R, Sakai Y, Yaguchi I,
1111 - 2000:21(11):895-900 doi:10.1053/eubi 1999-187 1109 57. Inoue T, Matsunaga R, Sakai Y, Yaguchi I, Takayanagi K, Morooka S. Insulin resistance affects
1110 endothelium-dependent acetylcholine-induced coronary artery response. Eur Heart J.
1111 2000;21(11):895-900. doi:1 1112 58. Neville MJ, Wittemans LBL, Pinnick KE, Todorčević M, Kaksonen R, Pietiläinen KH, Luan J, Scott RA,
1113 Wareham NJ, Langenberg C, et al. Regional fat depot masses are influenced by protein-coding gene 1111 2000;21(11):895-900. doi:10.1053/euhj.1999.1872 1112 58. Neville MJ, Wittemans LBL, Pinnick KE, Todorčević M, Kaksonen R, Pietiläinen KH, Luan J, Scott RA,
1113 Wareham NJ, Langenberg C, et al. Regional fat depot masses are influenced by protein-coding gene
1115 59 Krai vareham NJ, Langenberg C, et al. Regional fat depot masses are inhacticed by protein-coding gene
1114 variants. PLoS One. 2019;14(5):e0217644. doi:10.1371/journal.pone.0217644
1115 L. Johnson AD et al. Pleiotropic genes fo 1114 variants. PLos One. 2019;14(5):e0217644. doi:10.1371/journal.pone.0217644
1115 59. Kraja AT, Chasman DI, North KE, Reiner AP, Yanek LR, Kilpeläinen TO, Smit
1116 1, Johnson AD, et al. Pleiotropic genes for metabolic s 1115 59. Kraja AT, Chasman DI, North KE, Reiner AP, Yanek LR, Kilpeläinen TO, Smith JA, Dehghan A, Dupuis
1116 J, Johnson AD, et al. Pleiotropic genes for metabolic syndrome and inflammation. Mol Genet Metab.
1117 2014;112 1117 3014;112(4):317-38. doi:10.1016/j.ymgme.2014.04.007
1117 2014;112(4):317-38. doi:10.1016/j.ymgme.2014.04.007 1117 2014;112(4):317-38. doi:10.1016/j.ymgme.2014.04.007

1118 60. Xu S, Ilyas I, Little PJ, Li H, Kamato D, Zheng X, Luo S, Li Z, Liu P, Han J, et al. Endothelial
1119 Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to
1120 Pharmacotherapies Pha 1119 Dystanction in Atheroscielotic Cardiovascular Diseases and Beyond: From Mechanism to
1120 Pharmacotherapies. Pharmacol Rev. 2021;73(3):924-967. doi:10.1124/pharmrev.120.000096
1121 010:7(2):77-86 doi:10.1038/preardio. 1120 Pharmacotherapies. Pharmacol Rev. 2021;73(3):924-967. doi:10.1124/pharmiev.120.000099
1121 61. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Re
1123 62. CVt X Bozal EK, Barcia Durá 1121 61. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol.
1123 62. Cyr Y, Bozal FK, Barcia Durán JG, Newman AAC, Amadori L, Smyrnis P, Gourvest M, Das D, Gildea
1124 M. Kaur, 1122 2010;7(2):77-86. doi:10.10387/ileardio.2009.228
1123 62. Cyr Y, Bozal FK, Barcia Durán JG, Newman A
1125 - atherosclerosis Proc Natl Acad Sci U.S.A. 2024:12 62. Cyr Y, Bozal FK, Barcia Durán JG, Newman AAC, Amadori L, Smyrnis P, Gourvest M, Das D, Gildea
1124 M, Kaur R, et al. The IRG1-itaconate axis protects from cholesterol-induced inflammation and
1125 atherosclerosis. Proc 1125 atherosclerosis. Proc Natl Acad Sci U S A. 2024;121(15):e2400675121. doi:10.1073/pnas.2400675121
1126 63. Fuentes F, Palomo I, Fuentes E. Platelet oxidative stress as a novel target of cardiovascular risk in
1127 frai atherosclerosis. Proc Natl Acad Sci U S A. 2024, 121(15):e2400075121. doi:10.1073/phas.2400075121
1125 63. Fuentes F, Palomo I, Fuentes E. Platelet oxidative stress as a novel target of cardiovascular risk i
1127 64. Monte 1126 63. Fuentes F, Falomo I, Fuentes E. Platelet oxidative stress as a novel target of cardiovascular risk in
1127 frail older people. Vascul Pharmacol. 2017;93-95:14-19. doi:10.1016/j.vph.2017.07.003
1129 platelet activi 1127 Frail older people. Vascul Pharmacol. 2017;93-95:14-19. doi:10.1016/j.vph.2017.07.003
1128 64. Montenont E, Echagarruga C, Allen N, Araldi E, Suarez Y, Berger JS. Platelet WD
1129 platelet activity and is associated w 64. Montenont E, Echagarruga C, Allen N, Araldi E, Suarez Y, Berger JS. Platelet WDR1 suppresses
1129 platelet activity and is associated with cardiovascular disease. Blood. 2016;128(16):2033-2042.
1130 doi:10.1182/blood-2 1131 65. Gleissner CA. Platelet-derived chemokines in atherogenesis: what's new? Curr Vasc Pharmacol. 1132 - 2012:10(5):563-9. doi:10.2174/157016112801784521 1132 2012;10(5):563-9. doi:10.2174/157016112801784521
1133 66. Zahid M. Mangin P. Lovau S. Hechler B. Billialc 1131 65. Gleissner CA. Platelet-derived chemokines in atherogenesis: what's new? Curr Vasc Pharmacol.
1132 - 2012;10(5):563-9. doi:10.2174/157016112801784521
1134 - alveonrotein, VI. as an antithrombotic, tamet . J. Thromb 1132 2012;10(5):563-5. doi:10.217-4/157016112801764521
1133 66. Zahid M, Mangin P, Loyau S, Hechler B, Billiald
1135 doi:10.1111/ith.12009 1134 glycoprotein VI as an antithrombotic target. J Thromb Haemost. 2012;10(12):2418-27.
1135 doi:10.1111/jth.12009
1136 67. Jeney V. Balla G. Balla J. Red blood cell. hemoglobin and heme in the progression of 1134 glycoprotein VI as an antithrombotic target. J Thromb Haemost. 2012,10(12):2418-27.
1136 67. Jeney V, Balla G, Balla J. Red blood cell, hemoglobin and heme in the progression of
1137 atherosclerosis Eront Physiol 2014 1135 doi:10.1111₁jth.12009
1136 67. Jeney V, Balla G
1137 atherosclerosis.Front P 1137 atherosclerosis. Front Physiol. 2014;5:379. doi:10.3389/fphys.2014.00379
1138 68. Clemetson KJ, Clemetson JM. Platelet collagen receptors. Thromb Haemost. 2001;86(1):189-97.
1139 69. Nielsen J atherosclerosis. Front Physiol. 2014;5:379. doi:10.3389/fphys.2014.00379
1138 68. Clemetson KJ, Clemetson JM. Platelet collagen receptors. Thromb Hac
1140 Schmidt EM. Sveinbiotnsson G et al. Biobank-driven genomic discover 1138 68. Clemetson KJ, Clemetson KI, Platelet collagen receptors. Thromb Haemost. 2001,00(1):189-97.
1139 69. Nielsen JB, Thorolfsdottir RB, Fritsche LG, Zhou W, Skov MW, Graham SE, Herron TJ, McCarthy 3
1141 fibrillation 1140 Schmidt EM, Sveinbjornsson G, et al. Biobank-driven genomic discovery yields new insight into atrial
1141 fibrillation biology. Nat Genet. 2018;50(9):1234-1239. doi:10.1038/s41588-018-0171-3
1142 70. Aragam KG. Jian 1140 Schmidt EM, Sveinbjornsson G, et al. Biobank-diven genomic discovery yields new insight into atrial
1141 fibrillation biology. Nat Genet. 2018;50(9):1234-1239. doi:10.1038/s41588-018-0171-3
1142 at al. Discovery and s 1141 Fibrillation biology. Nat Genet. 2010,90(9):1234-1239. doi:10:1030/341500 010 0171-3
1142 70. Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, Weeks EM, Wang M, Hi
1143 in over a million participants. Nat Ge 1142 70. Aragam KG, Jiang T, Goel A, Kanoni S, Wolford Bri, Atri BS, Weeks EM, Wang M, Hindy G, Zhou W,
1143 et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease
1145 71 G 1143 et al. Discovery and systematic characterization of risk variants and genes for colonary artery disease
1144 in over a million participants. Nat Genet. 2022;54(12):1803-1815. doi:10.1038/s41588-022-01233-6
1145 Ionsdo in over a million participants. Nat Genet. 2022;54(12):1803-1815. doi:10.1038/s41588-022-01233-6
1145 71. Ghouse J, Tragante V, Ahlberg G, Rand SA, Jespersen JB, Leinøe EB, Vissing CR, Trudsø L,
1146 Jonsdottir I, Banasik 1146 Jonsdottir I, Banasik K, et al. Genome-wide meta-analysis identifies 93 risk loci and enables risk
1147 prediction equivalent to monogenic forms of venous thromboembolism. Nat Genet.
1148 2023;55(3):399-409.doi:10.103 1147 prediction equivalent to monogenic forms of venous thromboembolism.
1148 2023;55(3):399-409. doi:10.1038/s41588-022-01286-7
1149 72. Shah S. Henrv A. Roselli C. Lin H. Sveinbiörnsson G. Fatemifar G. Hedman Å K. Wilk J 1149 72. Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, Hedman Å K, Wilk JB, Morley MP,
1150 Chaffin MD, et al. Genome-wide association and Mendelian randomisation analysis provide insigh 1148 2023;55(3):353-409. doi:10.1038/s41588-022-01286-7
1149 72. Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G
1151 into the pathogenesis of beart fail 1149 72. Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, Heanan A K, Wilk JB, Morley MI,
1150 Chaffin MD, et al. Genome-wide association and Mendelian randomisation analysis provide insights
1151 into the 1150 Chaffin MD, et al. Genome-wide association and Mendelian randomisation analysis provide insights
1151 into the pathogenesis of heart failure. Nat Commun. 2020;11(1):163.
1153 73 van Zuvdam NR Stihy A Abdalla M Austin 1151 into the pathogenesis of heart failure. Nat Commun. 2020,11(1):163.
1152 doi:10.1038/s41467-019-13690-5
1154 Ablavist E Di Jiao C Sandbolm N et al Genome-Wide Association Study of Perinheral Artery Disease. 1152 doi:10.1038/s41467-019-13090-9
1153 73. van Zuydam NR, Stiby A, A
1154 Ahlqvist E, Di Liao C, Sandholm N, 73. van Zuydam NR, Stiby A, Abdalla M, Austin E, Dahlström EH, McLachlan S, Vlachopoulou E,
1154 – Ahlqvist E, Di Liao C, Sandholm N, et al. Genome-Wide Association Study of Peripheral Artery Disease.
1155 – Circ Genom Pre 1156 174. Mishra A, Malik R, Hachiya T, Jürgenson T, Namba S, Posner DC, Kamanu FK, Koido M, Le Grand Q, 1157
1157 15 Shi M, et al. Stroke genetics informs drug discovery and risk prediction across ancestries. Nature. 1155 Circ Genom Pecis Med. 2021,14(5):e002862. doi:10.1161/circgen.119.002862
1156 74. Mishra A, Malik R, Hachiya T, Jürgenson T, Namba S, Posner DC, Kamanu FI
1158 2022:611(7934):115-123. doi:10.1038/s41586-022-05165-3 1156 74. Mishra A, Malik R, Hachiya T, Jurgenson T, Namba S, Posner Dc, Kamanu FK, Koido M, Le Grand Q, 1157 Shi M, et al. Stroke genetics informs drug discovery and risk prediction across ancestries. Nature.
1158 2022;611 1157 Shi M, et al. Stroke genetics informs drug discovery and risk prediction across ancestries. Nature.
1158 2022;611(7934):115-123. doi:10.1038/s41586-022-05165-3
1150 randomization: from bynothesis test to 'Mendelian de 2022;611(7934):115-123. doi:10.1038)341586-022-05165-5
1159 75. Tobin MD, Minelli C, Burton PR, Thompson JR. Co
1161 doi:10.1083/ije/dvb016 1159 75. Tobin MD, Minelli C, Burton PK, Thompson JK. Commentary: development of Mendelian
1160 randomization: from hypothesis test to 'Mendelian deconfounding'. Int J Epidemiol. 2004;33(1):26-9.
1161 doi:10.1093/ije/dyh01 1160 randomization: from hypothesis test to 'Mendelian deconfounding'. Int J Epidemiol. 2004;33(1):26-9.
1161 doi:10.1093/ije/dyh016
. 1161 doi:10.1093/ije/dyh016

1162 76. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S,
1163 McVean GA, Abecasis GR. A global reference for human genetic variation. Nature.
1164 1163 McVean GA, Abecasis GR. A global reference for human genetic variation. Nature.
1164 2015;526(7571):68-74. doi:10.1038/nature15393
1165 77. Finucane HK, Reshef YA, Anttila V, Slowikowski K, Gusev A, Byrnes A, Gazal S,

1164 2015;526(7571):6874; doi:10:1036)/ididicity353
1165 77. Finucane HK, Reshef YA, Anttila V, Slowikow
1167 tissues and cell types. Nat Genet. 2018:50(4):621-1166 Shoresh N, et al. Heritability enrichment of specifically expressed genes identifies disease-relevant
1167 tissues and cell types. Nat Genet. 2018;50(4):621-629. doi:10.1038/s41588-018-0081-4
1168 78. Human genomics.

1166 Shoresh N, et al. Heritability ennemient of specifically expressed genes identifies disease-relevant
1167 tissues and cell types. Nat Genet. 2018;50(4):621-629. doi:10.1038/s41588-018-0081-4
1168 zegulation in humans, 1167 tissues and cell types. Nat Genet. 2018;50(4):021-629. doi:10.1038/s41588-018-6014
1168 178. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: mu
1169 1170 179. Eoley CN Staley IP Breen PG Sun BB K

1168 78. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene 1170 regulation in humans. Science. 2015;348(0235):648-60. doi:10.1126/science.1202110
1170 79. Foley CN, Staley JR, Breen PG, Sun BB, Kirk PDW, Burgess S, Howson JMM. A f
1171 2021:12(1):764 doi:10.1038/c41467-020-20885-8

1170 79. Foley CN, Staley JR, Breen PG, Sun BB, Kirk PDW, Burgess S, Howson JMM. A fast and efficient
1171 colocalization algorithm for identifying shared genetic risk factors across multiple traits. Nat Commun.
1173 80 Du

1172 2021;12(1):764. doi:10.1038/s41467-020-20885-8
1173 80. Duncan LE, Shen H, Ballon JS, Hardy KV, Noordsy DL, Levinson DF. Genetic Correlation Profile of
1174 Schizophrenia Mirrors Epidemiological Resu 1172 2021;12(1):764. doi:10.1038/s41467-020-20885-8
1173 80. Duncan LE, Shen H, Ballon JS, Hardy KV, Noo
1175 (22011.2) Cases of Schizophrenia, Schizophrenul, 2 1173 80. Duncan LE, Shen H, Ballon JS, Hardy KV, Noordsy DL, Levinson DF. Genetic Correlation Frome of
1174 Schizophrenia Mirrors Epidemiological Results and Suggests Link Between Polygenic and Rare Variant
1176 81 Chung D

1174 Schizophrenia Mirrors Epidemiological Results and Suggests Elin Between Folygenic and Rare Variant
1176 81. Chung D, Yang C, Li C, Gelernter J, Zhao H. GPA: a statistical approach to prioritizing GWAS results
1177 by 1175 (22q11.2) Cases of Schizophrenia. Schizophr Bull. 2018,44(6):1350-1361. doi:10.109393chbul/sbx174
1176 81. Chung D, Yang C, Li C, Gelernter J, Zhao H. GPA: a statistical approach to prioritizing GWAS resul
1178 doi:10 1176 81. Chung D, Yang C, Li C, Gelernter J, Zhao H. Gratistical approach to prioritizing GWAS results
1178 by integrating pleiotropy and annotation. PLoS Genet. 2014;10(11):e1004787.
1179 82 Purcell S Neale B Todd-Brown K

1177 by integrating pietotropy and annotation. PLoS Genet. 2014;10(11):e1004787.
1179 82. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI,
1180 Daly ML et al. BUNK: a tool 1179 doi:10.1371/journal.pgen.1004787
1179 82. Purcell S, Neale B, Todd-Brown
1181 Am Hum Genet 2007:81(3):559.7 82. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, 180 Daly MJ, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses.
1181 Am J Hu

1182 83. Darrous L, Mounier N, Kutalik Z. Simultaneous estimation of bi-directional causal effects and
1183 heritable confounding from GWAS summary statistics. Nat Commun. 2021;12(1):7274. 1181 Am J Hum Genet. 2007;81(3):559-75. doi:10.1086/513759
1182 83. Darrous L, Mounier N, Kutalik Z. Simultaneous estii
1184 - doi:10.1038/s41467-021-26970-w 1182 83. Darrous E, Mounier N, Kutalik Z. Simultaneous estimation of bi-directional causal effects and
1183 heritable confounding from GWAS summary statistics. Nat Commun. 2021;12(1):7274.
1185 84 Burges S. Bowden L. Fall

1184 doi:10.1038/s41467-021-26970-w
1185 84. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity Analyses for Robust Causal
1185 Inference from Mendelian Pandomization Analyses with Multiple Genetic Variante 1185 am Burgess S, Bowden J, Fall T,
1186 Inference from Mendelian Rando
1187 - 2017:28(1):30-42 doi:10.1097/ede 84. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity Analyses for Robust Causal
1186 Inference from Mendelian Randomization Analyses with Multiple Genetic Variants. Epidemiology.
1187 2017;28(1):30

1188 in 85. In Ray D, Chatterjee N. A powerful method for pleiotropic analysis under composite null hypothesis
1189 in Lidentifies movel Ishared Toci Detween Type 2 Diabetes and Prostate Cancer. PLoS Genet. 1187 2017;28(1):30-42. doi:10.1097/ede.000000000000000933
1188 85. Ray D, Chatterjee N. A powerful method for pleiotr
1180 2020:16(12):e1009218. doi:10.1371/journal pgen 10092 1189 identifies novel shared loci between Type 2 Diabetes and Prostate Cancer. PLoS Genet.
1190 2020;16(12):e1009218.doi:10.1371/journal.pgen.1009218
1191 86 Watanahe K Taskesen E van Boshoven A Posthuma D Eunctional manni

1189 identifies novel shared loci between Type 2 Diabetes and Prostate Cancer. PLoS Genet.
1190 2020;16(12):e1009218. doi:10.1371/journal.pgen.1009218
1191 senatic associations with FUMA Nat Commun 2017:8(1):1826 doi:10.10 2020,16(12):e1009218. doi:10.1371/journal.pgen.1009218
1191 86. Watanabe K, Taskesen E, van Bochoven A, Posthuma
1193 87. Kircher M. Witten DM. Jain B. O'Boak BJ. Cooper G 1191 86. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of
1192 genetic associations with FUMA. Nat Commun. 2017;8(1):1826. doi:10.1038/s41467-017-01261-5
1193 87. Kircher M, Witten D

1192 genetic associations with FUMA. Nat Commun. 2017;8(1):1820. doi:10.1038/s41467-017-01261-9
1193 87. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework
1195 80:10.1038/pg.2892 87. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for
1194 - estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310-5.
1196 - 88. Boyle AP Hong EL H

1195 doi:10.1038/ng.2892
1196 88. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, Karczewski KJ, Park J, Hitz BC,
1197 Weng S, et al. Annotation of functional variation in personal genomes using RegulomeDB. 1195 doi:10:1030/ng.2022
1196 88. Boyle AP, Hong I
1197 Weng S, et al. Annot 1196 88. Boyle AI, Hong EL, Hammann M, Cheng I, Schaub MA, Kasowski M, Karczewski KJ, Park J, Hitz BC,
1197 Weng S, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome
1198 89. Kundaje A.

1197 Weng S, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome
1198 Res. 2012;22(9):1790-7. doi:10.1101/gr.137323.112
1199 89. Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-M 1198 Res. 2012;22(9):1790-7. doi:10.1101/gr.137323.112
1199 89. Kundaje A, Meuleman W, Ernst J, Bilenky M, Y
1201 - 2015:518(7539):317-30. doi:10.1038/pature14248 89. Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, Kheradpour P, Zhang Z, 1200 Wang J, Ziller MJ, et al. Integrative analysis of 111 reference human epigenomes. Nature.
1201 2015;518(7539):317-30. doi

1202 90. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, Plagnol V. Bayesian
1203 test for colocalisation between pairs of genetic association studies using summary statistics. PLoS 1201 2015;518(7535):317-30. doi:10.1038) nature14248
1202 90. Giambartolomei C, Vukcevic D, Schadt EE, Fra
1204 6enet 2014:10(5):e1004383. doi:10.1371/journal 1202 90. Giambartolomer C, Vukcevic D, Schadt EE, Franke E, Fringoram AD, Wallace C, Fragnol V. Bayesian
1203 test for colocalisation between pairs of genetic association studies using summary statistics. PLoS
1205 91. Wal

1203 test for colocalisation between pairs of genetic association studies using summary statistics. PLOS
1204 Genet. 2014;10(5):e1004383. doi:10.1371/journal.pgen.1004383
1205 91. Wallace C. Eliciting priors and relaxing t 1204 Genet. 2014;10(5):e1004383. doi:10.1371/journal.pgen.1004383
1205 91. Wallace C. Eliciting priors and relaxing the single causal 1205 91. Wallace C. Eliciting priors and relaxing the single causal variant assumption in colocalisation

-
-
- 1206 analyses. PLos Genet. 2020,16(4):e1008720. doi:10.1371/journal.pgen.1008720
1207 92. Gerring ZF, Mina-Vargas A, Gamazon ER, Derks EM. E-MAGMA: an eQTL
1208 10011:37(16):2245-2249 doi:10.1093/bioinformatics/htab115 1207 92. Gerring Zr, Mina-Vargas A, Gamazon ER, Derks EM. E-MAGMA: an eQTE-informed method to
1208 identify risk genes using genome-wide association studies: a view from Mendelian randomization
1210 93 7bu H. Zhou X. Trans
-
- identify risk genes using genome-wide association study summary statistics. Bioinformatics.
1209 2021;37(16):2245-2249. doi:10.1093/bioinformatics/btab115
1210 93. Zhu H, Zhou X. Transcriptome-wide association studies: a v
- 1211 Quant Biol. 2021;9(2):107-121. doi:10.1007/s40484-020-0207-4
1212 94. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA:
- 1210 93. Zhu H, Zhou X. Transcriptome-wide association studies: a view from Mendelian randomization.
1211 Quant Biol. 2021;9(2):107-121. doi:10.1007/s40484-020-0207-4
1212 data BloS Comput Biol. 2015:11(4):e1004219. doi:10 1211 Quant Biol. 2021;9(2):107-121. doi:10.1007;340404-020-0207-4
1212 data. PLoS Comput Biol. 2015;11(4):e1004219. doi:10.1371/journ
1214 - 95 - Zhou Y. Zhou B. Bache L. Chang M. Khodabakhshi AH. T
-
- 1212 94. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS
1213 data. PLoS Comput Biol. 2015;11(4):e1004219. doi:10.1371/journal.pcbi.1004219
1215 Metascape provides a biologist-orie
- 1213 data. PLos Comput Biol. 2015;11(4):e1004219. doi:10.1371/journal.pcbi.1004219
1214 95. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Be
1215 Commun 2019:10(1):1523 doi:10.1038/s41467-019-09234-6 95. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK.
1215 Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat
1216 Commun. 2019;10(1):1523. 1215 Metascape provides a biologist oriented resource for the analysis or systems-level datasets. Nat
1216 Commun. 2019;10(1):1523. doi:10.1038/s41467-019-09234-6
1217 96. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powel
-
- 1216 Commun. 2015,10(1):1523. doi:10.1036/s41467-015-05234-6
1217 96. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, N
1218 gene targets. Nat Genet. 2016:48(5):481.7. doi:10.1038/ng.35 1218 Visscher PM, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait
1219 gene targets. Nat Genet. 2016;48(5):481-7. doi:10.1038/ng.3538
- gene targets. Nat Genet. 2016;48(5):481-7. doi:10.1038/ng.3538 1215 gene targets. Nat Genet. 2016;48(5):481-7. doi:10.1038/ng.3538
1220

1220

¹²²²**Table 1: Overview of 29 blood cell traits and 6 cardiovascular diseases included**

¹²²³**in this study**

- 1224 Note: Overview of 29 blood cell traits and 6 cardiovascular diseases, abbreviations as
1225 used throughout the manuscript, associated PubMed ID, Data source and Year of
- 1225 used throughout the manuscript, associated PubMed ID, Data source and Year of 1226 publication, the sample size, population and reference genome on which summary
- 1226 publication, the sample size, population and reference genome on which summary
1227 statistics are based, and the number of SNPs included in the original summary
- 1227 statistics are based, and the number of SNPs included in the original summary
1228 statistics, before we applied filtering.
- statistics, before we applied filtering.

1234 Genome-wide genetic associations between BCTs and CVDs. Orange or green 1235 borders highlight significant genetic correlations (with estimates provided) if they 1236 were FDR significant (FDR < 0.05) or nominally significant (p < 0.05), respectively.

1237

¹²³⁹**Figure 2: Forest plot of the bidirectional causal relationship between BCTs and** ¹²⁴⁰**CVDs**

1241 LHC-MR analysis was used to detect (a) forward (BCTs \rightarrow CVDs) and (b) reverse
1242 (CVDs \rightarrow BCTs) causal effects. Estimates and 95% confidence intervals are shown as

 $(CVDs \rightarrow BCTs)$ causal effects. Estimates and 95% confidence intervals are shown as

1243 dots and error bars, respectively.

Figure³

¹²⁴⁷**BCTs and six major CVDs**

1248 The three circular dendrograms included three BCTs (central points, including [a] 1249 leukocytes, [b] platelets, and [c] erythrocytes) and six CVDs (first circle), resulting in ¹²⁵⁰66, 24, and 84 trait pairs (second circle). A total of 156, 81, and 192 pleiotropic loci 1251 were identified in 43, 13, and 58 trait pairs for (a) leukocyte-CVDs, (b) platelet-CVDs, 1252 and (c) erythrocyte-CVDs, respectively (third circle). Significant pleiotropic genes 1253 were further identified by MAGMA and EMAGMA, and a total of 936 pleiotropic 1254 genes co-localized for paired traits. For trait pairs with more than three pleiotropic 1255 genes, we only displayed the top three pleiotropic genes according to the priority of 1256 candidate pleiotropic genes (fourth circle).

Figure1

Figure2

Figure3

